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Abstract 
Recent study suggested that the anti-platelet effect of nicergoline is caused by inhibiting 
agonist-evoked Ca2+ signalling by disrupting the normal localization of the dense tubular 
system in human platelets.  This effect is brought about by the disruption of the cortical 
microtubule bundle which plays a role in holding the dense tubular system in its normal 
location. However, these previous studies did not define the mechanism by which 
nicergoline induces this disruption of the cortical microtubule bundle.  In this study we 
aimed to further elucidate the mechanism by which nicergoline could disrupt the 
localization of the microtubules in human platelets.  To do this we have examined the 
effect of inhibitors of microtubule motor proteins such as kinesin, dyneins and myosin, 
as well as inhibitors of microtubule deacetylases to see whether these can mimic or 
modulate the effects of nicergoline on platelet Ca2+ signalling and functional responses. 
These experiments have demonstrated that myosin, dyneins and histone deacetylases 
are not the targets of nicergoline due to inhibitors of these targets failing to recreate the 
effects of nicergoline in both Ca2+ signalling and platelet function assays.  In contrast, 
our data does demonstrate the potential for kinesins to be a target of nicergoline’s 
action, as an inhibitor of these motor proteins recapitulates the effect of this drug on 
thrombin-evoked Ca2+ signalling and platelet function assays.  In addition, combined 
treatment with both drugs does not produce cumulative effects suggesting that they are 
working through the same pathway. These data give further insight towards the 
mechanism underling the anti-platelet effect of nicergoline and suggest an important 
role for the platelet molecular motor proteins in regulating platelet function and to be a 
possible target of action for a novel anti-platelet therapy in future. 
13 
 
1. Introduction  
  1.1 Basic Principles of Haemostasis  
Haemostasis involves a set of interrelated mechanisms which are triggered by damage 
to blood vessels that helps the circulation maintain its functional integrity (Furie et al., 
2008). Upon damage to the vessel wall, a coordinated sequence of events elicited by 
the local activation of platelets helps the blood vessel to prevent further bleeding and 
allow it to regain its normal structure and function (Fig 1.1). In the undamaged vessel, 
platelets are quiescent and unable to aggregate. The intact endothelial lining of the 
vessel wall helps keep platelets from activation by producing a number of substances 
which inhibit platelet activation, such as prostacyclin and nitric oxide (Ignarro et al., 
1987; Palmer et al., 1987; Marcus et al., 2002). Endothelial cells further prevent blood 
clotting through expression of the ectonucleotidase, CD39, on their cell surface, which 
reduces autocrine signalling between platelets (Marcus et al., 2005). 
Upon damage to the blood vessel, the inhibitory endothelial lining is removed and 
platelets are activated by their exposure to the subendothelial matrix, which contains 
adhesive ligands such as collagen, which can directly bind and activate platelets (Furie 
et al., 2008) as well as tissue factor which activates the extrinsic coagulation pathway 
leading to local production of the platelet agonist, thrombin (Vu et al., 1991). This initial 
stage of activation includes the adhesion of platelets to the subendothelial matrix at the 
site of injury (adhesion), triggering platelet activation which causes platelets to spread 
and secrete their granules to recruit other circulating platelets (recruitment).  
14 
 
Platelet stimulation also triggers the activation of the platelet fibrinogen receptor, 
integrin αIIbβ3, which allows platelets to create an aggregate through binding to one 
another via fibrinogen (Cohesion; Brass et al., 2011). This initial clot is then stabilized 
further by the activation of the clotting cascade leading to creation of a fibrin scaffold 
that mechanically supports the thrombus against the effects of flowing blood 
(Stabilization; Brass et al., 2011). Clot retraction is the final event of thrombus formation 
which helps to bring the damaged vessel wall together and allow the final wound to 
begin to heal (Feghhi & Sniadecki, 2011). 
 
 
 
 
 
 
 
 
 
 
 
15 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Fundamental steps of haemostasis: The intact endothelium prevents activation of resting 
platelets through secretion of inhibitory messengers such as prostacyclin and nitric oxide. Upon vascular 
damage, platelets are exposed to the subendothelial collagen and/or locally-formed thrombin which 
triggers their activation so they can adhere at the site of damage.  This initial layer of activated platelets 
releases autocrine messengers such as ADP and thromboxane A2 which help activate and recruit more 
platelets to the forming thrombus, where they are able cohere with each other via fibrinogen and the 
activated integrin αIIbβ3 (Figure reproduced from Brass et al., 2006). 
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  1.2 Inappropriate platelet activation elicits pathological blood clotting 
 responses 
The normal haemostatic pathway is principally controlled by platelet activation 
responses – thus when platelets have an insufficient reaction to vessel injury, this can 
lead to a tendency for the affected individual to have a propensity to suffer from 
excessive bleeding in response to injury (called a bleeding diathesis). The complex, 
multi-step nature of platelet activation can be seen in the human conditions that result 
from molecular defects in each of the basic steps of haemostasis identified above. This 
includes failure to adhere to the damaged subendothelial matrix (e.g. Von Willebrand’s 
disease, Bernard Soulier syndrome), failure to recruit circulating platelets (e.g. storage 
pool disorders, Hermansky-Pudlak syndrome), failure to aggregate (e.g. Glanzmann’s 
thrombasthenia) and failure to stabilize the thrombus (e.g. Haemophilia, Scott’s 
syndrome). In contrast, platelet activation in undamaged vessels or uncontrolled 
thrombus formation can lead to vascular obstruction. Such unwanted platelet activation 
underlies a range of cardiovascular disorders such as myocardial infarction, stroke or 
deep vein thrombosis (Furie et al., 2008). Thus by understanding the normal cell biology 
of platelets it may be possible to uncover new ways of treating patients with overactive 
or underactive clotting responses. 
    
  1.3 Platelet structure 
Platelets are the smallest blood cells in the body, with 150-400 x109 platelets found in 
each litre of blood. Unstimulated platelets are disc-shaped cells of about 2-3 µm in 
diameter and 6-8 fL in volume (Zucker-Franklin, 1997). Platelets are anucleate cells 
which also lack a number of other core cellular organelles such as the mitotic apparatus 
17 
 
and Golgi apparatus (Gibbins, 2004; Zucker-Franklin, 1997). As shown in Fig 1.2, 
platelets have a number of other key ultrastructural features which are the presence of a 
thick glycocalyx (Zucker-Franklin & Petursson, 1984), an invagination of their plasma 
 
 
 
 
Figure 1.2: Diagram showing the basic structure of a resting platelet: Platelets are discoid cells 
maintained by the presence of a submembrane cortical microtubule bundle (CMB)  These cells also 
possess a specialized invagination of their plasma membrane called the open canalicular system (OCS).  
The OCS spreads throughout the cell and comes into close contact with the main platelet Ca
2+
 store, the 
dense tubular system (DTS) – this structure is called the membrane complex. In addition to this platelets 
possess a number of different secretory granules (α-granules, dense granules and lysosomes) which 
possess a range of biologically-active molecules which can contribute to haemostasis and inflammatory 
processes within the body.  The platelet is also notable amongst blood cells for possessing a thick 
glycocalyx, which includes a range of glycoproteins important for platelet activation.  
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membrane system called the open canalicular system (OCS) and the presence of a 
number of characteristic organelles such as the dense tubular system (DTS), the alpha 
and dense granules. 
 
   1.3.1 Platelet discoid shape and the cytoskeleton 
    1.3.1.1 The cortical microtubule bundle 
The resting platelets discoid appearance is a characteristic feature of these blood cells 
and is thought to be maintained by the presence of a cortical microtubule bundle which 
lies directly under the platelet plasma membrane (Behnke, 1965; Italiano et al., 2003; 
White & Krivit, 1967; White, 1968a; White & Rao, 1998). Microtubules are made up of 
heterodimers of globular α-tubulin and β-tubulin polypeptides (Downing and Nogales, 
1998; Sullivan, 1988). The platelet cortical microtubule bundle is thought to consist of a 
single microtubule chain made up of significant quantities of β1 tubulin (Schwer et al., 
2001). The cortical microtubule polymer is rolled up into 8-12 coils giving the 
appearance of a bundle of closely associated filaments when observed in cross section 
(White & Krivit, 1967; White & Rao, 1998; Italiano et al., 1999). The loose coiling of the 
cortical microtubule bundle has been shown to be influenced by kinesin and dynein 
molecular motors, which work antagonistically in the resting platelet to prevent the 
contraction of the cortical microtubule ring (Diagouraga et al., 2014). 
It has been found that β1-tubulin is the predominant isoform of β-tubulin present in 
platelets (Wang et al., 1986; Lewis et al., 1987; Lecine et al., 2000) and its expression is 
largely restricted to the megakaryocyte lineage (Schwer et al., 2001). It has been found 
that mice deficient in the platelet-specific β1-tubulin protein had reduced numbers of 
19 
 
platelets due to an effect of this loss on thrombopoiesis, as well as spherical platelets 
due to the reduced number of microtubule coilings observed in these cells (Schwer et 
al. 2001). Interestingly these platelets showed a reduction in some (but not all) 
responses to in vitro stimulation with thrombin (Schwer et al., 2001; Italiano et al., 
2003). These data suggest that the maintenance of the normal cortical microtubule 
bundle may play a role in eliciting normal platelet function (Schwer et al., 2001). 
   
    1.3.1.2 The cortical actin cytoskeleton 
Platelets also contain an actin microfilamentous system. Actin filaments (F-actin) are 
made of polymers of globular actin proteins. In resting platelets, around 30-40% of actin 
molecules are assembled into the microfilaments, with the rest available for 
polymerization u;2pon platelet activation (Fox et al., 1984). In the resting platelet, much 
of the F-actin is found congregated in a cortical actin ring (Rosado et al., 2000). 
However disassembly of the cortical actin ring has been shown to have limited effect on 
resting platelet shape (White & Rao, 1998). In the resting state the actin microfilaments 
have all the cellular organelles arranged in a way that they are away from the plasma 
membrane as well as separate from each other. However when the cell is activated, the 
actin filaments start to form filaments within the cell periphery and also within the 
developing filopodia (Fox, 1993). The actin filaments assemble into parallel bundles 
which allows the platelet to spread over the exposed subendothelial matrix (Fox, 1993). 
The actin cytoskeleton has been shown to bind indirectly to the cytoplasmic tails of 
Glycoprotein Ib-IX-V (GPIb-IX-V) and the integrin αIIbβ3 indirectly via a number of actin-
binding proteins as well as elements of the contractile system including myosin and 
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calmodulin.  Collectively this contractile system helps translocate these receptors to the 
external surface of the resting platelet (Michelson, 2013). 
 
   1.3.2 Platelet membrane organization 
Platelet membrane structure is principally made up of two highly-organised membrane 
systems; the open canalicular system (OCS; which is originated from the platelet 
surface; Fig 1.3; Behnke, 1967; Behnke, 1968) and the dense tubular system (DTS; 
which is derived from the smooth endoplasmic reticulum of the megakaryocytes; White, 
1972). 
 
    1.3.2.1 The open canalicular system 
The OCS is known to derive from the remnants of the megakaryocyte’s demarcation 
membrane system (DMS; Zucker-Franklin, 1989). The OCS is made up of a complex 
series of invaginations of the plasma membrane of the platelet – and can be seen in 
electron microscopic cross-sections as glycocalyx-lined clear vacuoles between the 
other cytoplasmic elements (Figure 4), which appear to have a similar composition to 
the platelet plasma membrane (White, 1972; van Nispen tot Pannerden et al., 2010). 
The channels of the OCS can be seen connected with the platelet exterior and remain 
open during platelet activation, cell shape change and release (White, 1973;  White, 
1974). The OCS serves to increase the surface area of the platelet exposed to plasma 
 
.  
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Figure 1.3:The structure of the platelet plasma membrane. Figure showing glycocalyx and 
invaginations of plasma membrane to form Open canalicular system (Modified from Frederick & Richard, 
1997). 
 
and allows communication of the deepest region of the platelet with the extracellular 
space (White, 1968a). Previous work has shown that the OCS acts as a two way 
channel both allowing for plasma-derived substances to be taken-up and stored in 
platelet secretory vesicles but also to allow the release of granule contents into the 
plasma during platelet activation (White, 1972). As such the OCS is considered a key 
channel for transport around the platelet.   
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Figure 1.4: Electron micrograph showing a cross-section through a platelet demonstrating the 
structural arrangements of the major membrane systems: DTS; dense tubular system, OCS; Open 
canalicular system, GI; glycogen and M; mitochondrion  (Reproduced from Zucker-Franklin, 1997). 
 
 
    1.3.2.2 The dense tubular system 
The other major membrane structure found within platelets is called the dense tubular 
system (Fig 1.4). The DTS is derived from the residual endoplasmic reticulum of the 
megakaryocyte (Behnke, 1968). Like the endoplasmic reticulum of other cells, the DTS 
stores large amounts of Ca2+ (Gerrard et al., 1978) and is known to be the principal site 
of agonist-evoked Ca2+ release upon platelet activation (Sage et al., 2011; See section 
1.5.). The DTS also contains the enzymes required for the synthesis of prostaglandins 
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(Cutler et al., 1978; Kaser-Glanzmann et al., 1978; Gerrard et al., 1976). The DTS can 
be selectively labelled in electron microscopic slices by cytochemically labelling this 
compartment utilizing a reaction catalyzed by the peroxidase activity associated with 
prostaglandin synthesis in the DTS (Gerrard et al., 1976). The DTS can also be 
characterized by the presence of proteins containing the endoplasmic reticulum 
retention signal, KDEL, which are selectively found in this location (van Nispen tot 
Pannerden et al., 2010).  
The DTS has been shown to closely associate with the cortical microtubule bundle in a 
number of electron microscopy studies – suggesting that the cortical microtubule bundle 
may be anchored to the DTS and may be responsible for its distribution in the platelet 
(Behnke, 1965; White, 1969; White, 1968b). Interestingly, the DTS has been shown to 
be rapidly reorganized upon platelet activation – suggesting that there are active 
mechanisms that control the distribution of this organelle within the platelet (Ebbeling et 
al., 1992). 
 
    1.3.2.3 The membrane complex 
Although the OCS and DTS are observed to form distinct membrane systems within the 
platelet, they can also be to be closely apposed to one another in a specific subregion 
of the platelet known as the membrane complex (White, 1972; van Nispen tot 
Pannerden et al., 2010; Fig 1.5).   
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Figure 1.5: Structure of the membrane complex. Cross section tomography scanning showing the two 
components of the platelet membrane system: (A and B) Continuities of the surface membrane forming 
the OCS (blue arrowheads) come in close contact with DTS membrane (white arrowheads) at the OCS 
neck regions. (C) The two components in 3D-imaging showing the association representing the 
membrane system. (D and E) Three-dimensional imaging showing the structure of the OCS (blue) and 
DTS (yellow). (F) 3D reconstruction showing the close apposition between the OCS and DTS 
(Reproduced from van Nispen tot Pannerden et al., 2010). 
 
 
The close apposition of these two membrane systems is unique among blood cells and 
the only equivalent structures in the human body are the nanojuctions created between 
the T-tubule and sarcoplasmic reticulum of striated muscles (Ezerman & Ishikawa, 
1967; Hagopian & Spiro, 1967), and the sarcoplasmic reticulum and plasma membrane 
in smooth muscle cells (van Breemen et al., 2013). This similarity in platelet and muscle 
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structure has long been established (Grette, 1962; White, 1967), yet  despite the 
membrane complex having being hypothesized to play a role in platelet Ca2+ signalling 
in an analogous manner to its role in striated muscle (White, 1972), the significance of 
this structure remains uncertain. In other cell types these nanometer-scale interactions 
of membranes are referred to as nanojunctions (van Breemen et al., 2013). The close 
interaction of transporters and channels involved in Ca2+ signalling here allow these 
nanojunctions to have Ca2+ signals which are isolated from the bulk cytosol and thus 
can create a specialized nanodomain which can allow Ca2+ to independently control a 
range of Ca2+-sensitive processes within the same cell type (van Breemen et al., 2013).  
 
   1.3.3 Other key platelet organelles 
Platelets also have a range of other membrane-bound organelles inside them including 
α-granules, dense granules and lysosomes (Figure 2). Platelets can also be seen to 
contain glycogen granules and mitochondria randomly distributed in the cytoplasm -  the 
presence of both mitochondria and glycogen suggested that oxidative phosphorylation 
and glycolysis both are an energy source for the cells (Zucker-Franklin, 1981).  
     
    1.3.3.1 α-granules 
The α-granules are the most abundant type of granule present within platelets, with 
around 40-80 α-granules seen in each cell (Harrison and Cramer, 1993; Reed, 2007). 
The α-granules are oval in shape and around 200-500nm in diameter (Fox, 1993). The 
α-granules contain zones of distinct electron density – including an electron-dense 
nucleoid where β-thromboglobulin, platelet factor 4 and proteoglycans are concentrated, 
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and an adjacent translucent area containing key proteins involved in haemostasis such 
as von Willebrand factor (vWF), factor V and fibrinogen (White, 1993; Maynard et al., 
2007; McRedmand, 2007). A range of other proteins (e.g. coagulation factors, adhesive 
proteins, chemokines, protease inhibitors, vascular endothelial growth factor and 
endostatin) are also found within the alpha granules either due to the biosynthesis of 
those proteins and packaging into the alpha granules in the megakaryocytes or by their 
uptake from the plasma by endocytosis (George, 1990; George, 1991). Previous work 
has suggested that contents of α-granules can be differentially released upon activation 
of the PAR-1 or PAR-4 thrombin receptors (Harrison and Cramer, 1993) although this is 
controversial and more recent evidence has disputed this claim (Sehgal & Storrie, 
2007,2009). The exocytosis of α-granules upon platelet activation allows the release of 
adhesive proteins (such as fibronectin and chemokines) that can take part in leukocyte 
and platelet activation at the site of vascular injury (Gear & Camerini, 2003). 
     
    1.3.3.2 Dense granules 
Dense granules are electron-dense organelles of around 20-30 nm in diameter 
observed in the platelet cytoplasm when viewed in cross section by electron microscopy 
(White, 1993). In contrast to alpha granules, every platelet contains only 3-8 dense 
granules per cell (White, 1993). Dense granules contain a high concentration of 
calcium, serotonin, adenosine diphosphate (ADP), adenosine triphosphate (ATP) and 
pyrophosphate (Ruizet al., 2004; Prada et al., 1967; White, 1968b; Martin et al., 1974), 
as well as membrane glycoproteins such as Integrin αIIbβ3, GPIb-V-IX and P-selectin. 
Platelet dense granule secretion is important for platelet aggregation as the release of 
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autocrine signalling molecules such as ADP, ATP and serotonin are known to play a 
role in triggering platelet recruitment to the growing thrombus (Nesbitt et al., 2003) 
through thei;r respective receptors on the platelet surface (P2Y1/P2Y12 receptors for ADP, 
P2X1 receptor for ATP and 5-HT2A receptor for serotonin). In addition, release of 
serotonin may also play a key role in vasoconstriction of smooth muscle cells in the 
media of the damaged blood vessel helping reduce blood flow through the damaged 
blood vessel (Lesurtel et al., 2006; McNicol & Israels, 1999). 
 
    1.3.3.3 Lysosomes 
Platelets also contain a small number of lysosomes. They originate from the endosomal 
membrane system (Huizing et al., 2008). Upon platelet activation, lysosomal secretion 
occurs at a slower rate and requires stronger agonist stimulation than the α- and dense 
granules (Kaushansky et al., 2010). Lysosomes contains a number of different 
hydrolases such as as β-glucuronidase, β-galactosidase, elastase, heparitinase, β-
glycerophosphatase and collagenase which are released upon platelet activation 
(Marcus et al., 1966, Bentfeld-Barker & Bainton, 1982). Lysosomal secretion at the site 
of vascular damage elicits release of elastase and collagenase at the site of thrombus 
formation – potentially playing a role in remodeling of the extracellular matrix of the 
damaged vessel (Zhang et al., 2001). Heparitinase release cleaves endothelial cell 
heparin and the resultant soluble heparin has been shown to function as an inhibitor of 
smooth muscle cell growth (Castellot et al., 1982). 
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  1.4. Megakaryocytes as a model system for studying the membrane complex  
Given the small diameter of the platelet and the nanometer scale of the open canalicular 
system, live cell imaging of the pericellular Ca2+ signals is difficult to localise to 
subregions of the platelet. In addition, it is not possible to genetically manipulate the 
anucleate platelet.  Megakaryocytes are the parent cell of the platelet, and as such 
much larger than the platelet (mature megakaryocytes range from 20-100 μm in 
diameter). Megakaryocytes eventually fragment into platelets through a coordinated 
series of developmental changes (Richardson et al., 2005).  
Importantly, megakaryocytes possess an invaginated membrane system analogous to 
the OCS of the platelet, called the demarcation membrane system (Yamada, 1957; 
Behnke, 1968; Nakao et al., 1968). The DMS extends inwardly through the 
megakaryocyte dividing it into small sections of cytoplasmic compartments which were 
previously thought to demarcate the location of future platelets (Breton-Gorius & Reyes, 
1976; Paulus et al., 1979; Tavassoli, 1980). Recent work has suggested that this 
system acts as a membrane reservoir needed to form the proplatelets (Yamada, 1957; 
Radley and Haller, 1982; Schulze et al., 2006). The DMS has been shown 
electrophysiologically to be continuous with the surface membrane of the 
megakaryocyte (Mahaut-Smith et al., 2003).    
Previous studies have tracked  the DMS using fluorescent membrane indicators 
(Mahaut-Smith et al., 2003), soluble extracellular fluid tracers (Mahaut-Smith et al., 
2003), or through fluorescent labelling of either GPIb (Eckly et al., 2013) or PIP2-binding 
proteins (Schulze et al., 2006). Recently, these techniques have been used to further 
study the origin of the DMS in the developing megakaryocyte. Tracking the formation of 
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the DMS has shown that its initial form, the pre-DMS, occurs early in the megakaryocyte 
development process and is found to extend from the cell surface into a perinuclear 
location between the lobules of the megakaryocyte nucleus (Eckly et al., 2013). From 
here the DMS develops in a more elaborate manner extending through the whole of the 
cytosol of the megakaryocyte.  Most importantly, in later stages of megakaryocyte 
development, the DMS can be seen to form intimate connections with the endoplasmic 
reticulum (ER) – creating a structure similar to the platelet membrane complex (Eckly et 
al., 2013). This ER-DMS association has also been observed by other investigators 
(Breton-Gorius & Guichard, 1972) suggesting this nanojunction is a key feature of 
mature megakaryocytes. 
The megakaryocyte therefore provides a potentially attractive model system as it 
possesses a proteome closely-related to that of the platelet, has a nanojunction similar 
to the membrane complex of platelets made up of the DMS and ER, and is open to 
genetic manipulation (e.g. Schulze et al., 2006). In addition, due to their larger size, 
using human megakaryocytes may help make live-cell imaging of microdomains of Ca2+ 
more feasible. Due to these favorable properties, megakaryocytes cultured from CD34+ 
haematopoietic stem cells may present a model system in which we can follow the 
development, structure and function of the platelet membrane complex.  
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   1.4.1 Principles of in vitro megakaryocyte culture 
The ability of stem cells to produce many kinds of cells upon proliferation and 
differentiation promises a wide scope of development in treating many diseases as well 
as future improvement in transfusion medicine. Our knowledge about in vitro culturing of 
megakaryocytes has been driven by the aim of further producing platelets in vitro from 
these cells, to support the increasing demand for platelet transfusions in patients who 
are thrombocytopenic due to chemotherapy or haematopoietic stem cell transplantation 
(Kessinger et al., 1988). This clinical need has driven an improvement of the methods 
used to derive mature megakaryocytes and functional platelets from CD34+ cells. A 
number of studies have shown the feasibility of effectively producing megakaryocytes 
and platelets in vitro from human stem cells from bone marrow, umbilical cord and 
peripheral blood through appropriate treatment with cytokines including thrombopoietin 
(Long et al., 1982; Gordon et al., 1990; Ogawa, 1993; Morita et al., 2011). In vitro 
production of platelets requires a consideration of the wide range of variables that can 
regulate megakaryocyte growth and development from hematopoietic stem cells 
(Reems et al., 2010). 
The most studied aspects of in vitro culturing of megakaryocytes is the composition of 
the cocktail of cytokines used to trigger proliferation, differentiation and growth of 
megakaryocytes. Thrombopoietin is considered to be the key cytokine responsible for 
triggering megakaryocyte growth and differentiation (Gurney et al., 1994; Alexander et 
al., 1996; Kaushansky et al., 1995), in addition to its important role in the preservation of 
the hematopoietic stem cell population (Kaushansky, 1999; Drachman, 2000). Other 
cytokines including Interleukin-3 (IL-3; Qudenrijn et al., 2000; Dolzhanskiy et al., 1997; 
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Schattner et al., 1996), stem cell factor (SCF; Dolzhanskiy et al., 1997; Cortin et al., 
2005), IL-6 (Proulx et al., 2003; Dolzhanskiy et al., 1997), IL-9 (Cortin et al., 2005; Fujiki 
et al., 2002) and IL-11 (De Brauyn et al., 2005; Matsunaga et al., 2006) act in synergism 
with thrombopoietin in increasing the megakaryocytes number. Other cytokines 
specifically IL-3, Flt-3 Ligand (De Bruyn et al., 2005; Matsunaga et al., 2006; Feng et al., 
2005; Sigurjonsson et al., 2004) and SCF (Sitnicka et al., 1996; Kobayashi et al., 1996) 
act with Thrombopoietin to assist the immature progenitor cells reproduction although 
some studies consider IL-3 as an inhibitor of megakaryocyte growth (Dolzhanskiy et al., 
1997). 
Another key variable is the type of media used to grow megakaryocytes - media 
containing serum were commonly used, however because serum may contain growth 
inhibitors (Luft et al., 1998), many companies have started to produce media with serum 
alternatives namely albumin, insulin and transferrin (Brunner et al., 2010; Bieback et al., 
2009). In addition, the physical and chemical conditions of the culture such as the partial 
pressure of oxygen (LaIuppa et al., 1998; Mostafa et al., 2000; Mostafa et al., 2001), 
media pH (Yang et al., 2002) and temperature (Proulx et al., 2004; Pineault et al., 2008) 
need to be regulated to meet the optimal conditions for megakaryocyte maturation and 
differentiation. Lastly, continuous swapping of culture media to get rid of metabolic 
waste products is important to prevent accumulation of waste materials such as 
ammonia and lactic acid, which inhibit megakaryocyte growth and improve the 
availability of oxygen, glucose and glutamine levels (Reems et al., 2010). 
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   1.4.2 Stages of megakaryocyte development 
To understand the success of any in vitro megakaryocyte cultures it is important to 
understand the normal stages of megakaryocyte development. The stages of 
megakaryocyte maturation and differentiation are distinguished by the cytoplasmic and 
nuclear changes that occur throughout the process of megakaryopoiesis and 
thrombopoiesis (Deutsch & Tomer, 2006). 
Megkaryocytes are derived from CD34+ haematopoietic stem cells found within the 
bone marrow of adults (Long et al., 1982; Gordon et al., 1990; Ogawa, 1993; Morita et 
al., 2011). Haematopoietic stem cells with CD34 protein were first identified in 1984 and 
have given special importance in considering the hematopoiesis in bone marrow (Civin 
et al., 1984). Nowadays evidence has shown that cells with CD34 protein can also 
occur in stromal, vascular and epithelial tissues (Sidney et al., 2014). 
The first stage of megakaryocyte development starts with about 20% of all the 
haematopoietic cells committed for platelet production called megakaryoblasts. A 
human marrow megakaryoblast is up to 24 micrometer in spherical diameter, the 
nucleus is somewhat large and mildly serrated containing poorly differentiated 
chromatin and multiple nucleoli.  Tiny Golgi complex, some of mitochondria and α-
granules with plenty of free ribosomes can be noticed in a few basophilic cytoplasm 
(Kaushansky et al., 2010). 
The early stages of megakaryopoiesis are characterized by the expression of the 
integrin αIIb gene (Tronik-Le Roux et al., 1995) and the cell surface protein integrin αIIbβ3 
becomes clear and active at these stages with a marked increase in the cytoplasmic 
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content of this integrin in its granular compartment (Bennett, 2005). In addition, the 
glycoprotein Ib-IX complex (Debili et al., 2001) and glycoprotein V (Hickey et al., 1993) 
are also expressed.  
Interestingly, the megakaryoblast starts to invaginate its plasma membrane which forms  
the demarcation membrane system (Breton & Reyes, 1976) which is thought to play a 
vital role in the process of  platelet  production later (Italiano & Shivdasani, 2003). 
The megakaryoblast shows a highly-lobular nucleus with increased chromosomal 
number ranging from 8-128 times that of normal cells which is characteristic of 
megakaryocytes and is created by repeated DNA replication without nuclear or 
cytoplasmic division in a process called endomitosis which is completed by the end of 
stage 2 of  megakaryopoiesis (Ebbe & Stohlman, 1965).  
The second stage is found in 25% of the megakaryocytes in bone marrow. This stage is 
characterised  by cytoplasmic expansion with less dense basophilic staining and plenty 
of organelles and platelet-specific α- granules which contain specific proteins such as 
fibrinogen and von Willebrand Factor (vWF; Henijnen et al., 1998; Handagama et al., 
1987) as well as mitochondria and dense granules. Cell size is up to 30 µm in diameter, 
the nucleus is multilobed and the demarcation membrane system becomes more 
extended and obvious with more prominent endomitosis of the nucleus (Kaushansky et 
al., 2010). 
In stages 3 and 4 of megakaryocyte maturation, the cytoplasm continues to expand and 
becomes acidophilic and cell size is up to 50 µm in diameter. These cells posses large 
numbers of ribosomes and a large multi-lobed, laterally-located, pyknotic nucleus. The 
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demarcation membrane system extends more and substitutes the endoplasmic 
reticulum and Golgi apparatus (Kaushansky et al., 2010). 
Furthermore, the megakaryocyte commences the formation of proplatelets (Fig 1.6) by 
the formation of long and precise cytoplasmic protrusions which extend as pseudopodia 
and are formed by exterior movement of the internal membranes (Patel et al., 2005) and 
serve to transport the organelles and other constitutive substances needed for platelet 
formation from the megakaryocyte cell body to the branched distal ends which 
represent the sites of future platelet production (Kaushansky et al., 2010). 
Proplatelet formation persists till the cytoplasm is totally exhausted and converted into 
proplatelets linked to each other by cytoplasmic filaments (Italiano et al., 1999; Andrews 
et al., 1993). The nuclear material is converted into an eccentric body containing scarce 
cytoplasm and finally decomposes (Patel et al., 2005). In the end, the proplatelet tips 
grow into masses which become the primary sites of platelet production and liberation 
(Patel et al., 2005) and this happens when the proplatelet masses start to release mono 
proplatelets due to the retraction which separate the proplatelets from the cell body 
(Italiano et al., 1999). The released proplatelets are a series of platelet-sized bodies 
connected in the middle by a shaft which thought to tighten gradually and detach 
releasing the platelet like particles (Patel et al., 2005). 
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Figure 1.6: Platelet production from the mature megakaryocyte. (A and B) Immature megakaryocyte 
cells undergo nuclear endomitosis, cytoplasmic maturation, microtubule differentiation and production of 
organelles. (C) Microtubules arranged at the cell periphery and pseudopod formation signalling the 
production of proplatelets. (D) Microtubules slide and support the pseudopods which elongate, bend and 
branch and trap the organelles distally to the site of platelet production. (E) The cell is changed into a 
stack of proplatelets which split up into platelets (figure reproduced from Patel et al., 2005) 
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  1.5. Platelet activation mechanisms 
   1.5.1 Platelet activation under blood flow requires platelet interaction with 
adhesive ligands of the subendothelial matrix 
Platelets normally freely circulate in the blood in quiescent form. In the event of 
disruption of the endothelial lining (e.g. vascular injury or rupture of an atherosclerotic 
plaque) a chain of reactions immediately starts which ultimately leads to platelets 
triggering the clotting of the blood. The inert nature of resting platelets comes about due 
to the platelet fibrinogen receptor, Integrin αIIbβ3, being in an inactive confirmation 
(Bennett, 2005). Upon vascular damage platelets encounter a number of chemical 
stimuli from the damaged vessel wall which can trigger platelet activation (e.g. collagen, 
thrombin, and adenosine triphosphate), these initial stimuli are able to trigger platelets 
to activate their integrin αIIbβ3 (Jackson et al., 2003) – leading to the platelets ability to 
bind to one another, and therefore to start to aggregate. 
Initial platelet tethering to the damaged vessel wall under conditions of arterial blood 
flow requires the binding of platelets to collagen via immobilised vWF.  This interaction 
occurs via the GP Ib-IX-V receptor for vWF (Weiss et al., 1978) – however this initial 
binding and platelet activation is weak and cannot by itself support irreversible binding 
to the damaged vessel wall (Kulkarni et al.,2000). Further activation of platelets requires 
stronger activation to elicit stable aggregates. 
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Figure 1.7: Primary haemostasis. A review of primary haemostasis showing the process of platelet 
aggregation which demonstrate the recruitment of nearby platelets activated by the exposed 
subendothelium at the site of damage, granule secretion and formation of first layer-platelet aggregation. 
The expression of vWF will help recruitment of more platelets by binding their GPIbα in a dynamic 
process between translocation and subtraction overwhelm by the interaction between surface αIIbβ3 
receptor of unsettled platelets and stable platelets. This interaction is mediated by plasma vWF or 
fibrinogen towards stable thrombus formation. Modified from Kulkarni et al., (2000). 
 
Previous work examining thrombus formation in vivo in the mesenteric artery of mice 
has indicated that there are two parallel stimuli that trigger platelet aggregation; platelet 
binding to subendothelial collagen, or activation through the local production of thrombin 
by the extrinsic coagulation cascade triggering platelet activation (Furie & Furie, 2008).  
The relative importance of these two pathways is uncertain and appears to depend on 
the experimental method used to induce vascular injury. For example, endothelial 
denudation elicited by treatment with ferric chloride triggered blood clotting principally by 
activating platelets via collagen exposure on the subendothelial matrix, whilst thrombus 
formation triggered by laser-induced injury to the vessel wall is principally dependent on 
thrombin production via activation of the extrinsic blood coagulation pathway (Furie & 
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Furie, 2008). Given both experimental stimuli are not representative of how a blood 
vessel is normally injured; it is likely that both of these activation pathways contribute to 
thrombus formation in vivo.  
 
   1.5.2 Platelet activation requires a rise in cytosolic Ca2+ concentration  
Platelet agonists such as collagen and thrombin evoke platelet activation through 
eliciting a rise in cytosolic Ca2+ concentration ([Ca2+]cyt; Rink & Sage, 1990). This rise in 
[Ca2+]cyt plays a central role in mediating blood clotting through its ability to control a 
range of different processes required for thrombus formation including adhesion, shape 
change, granule secretion, platelet cohesion, thromboxane and thrombin production and 
clot retraction (Born, 1972; Grette, 1962; Heptinstall, 1976; Heemskerk et al., 2013; 
Knight & Scrutton, 1984). Therefore understanding how calcium signals are generated 
will allow us to understand how platelets become activated, and so we might be able to 
identify novel strategies for preventing unwanted platelet aggregation as occurs in a 
variety of cardiovascular disorders including heart attack, stroke and deep vein 
thrombosis by preventing these Ca2+ signals.  
 
   1.5.3 Control of [Ca2+]cyt in unstimulated platelets 
In the undamaged vessel, the inactive platelet is kept quiescent by maintaining [Ca2+]cyt 
at very low levels (≈ 50-100 nM). This is achieved through the parallel use of a series of 
primary active transporters of Ca2+ which remove Ca2+ from the platelet cytosol either by 
sequestration into intracellular Ca2+ stores (Sage et al., 2011) or through removal of 
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Ca2+ across the plasma membrane (Johansson & Haynes, 1988; Jones et al., 2010; 
Valant et al., 1992).   
Platelets principally sequester Ca2+ into the dense tubular system using the 
Sarco/endoplasmic reticulum Ca2+-ATPase isoform 2b (SERCA2b; Papp et al., 1991; 
Cavallini et al., 1995; Kovacs et al., 1997). In addition, platelets are also found to 
possess the SERCA3 isoform which appears to be related to an acidic Ca2+ store in 
platelets (Lopez et al., 2006; Ruiz et al., 2004). These distinct SERCA-dependent Ca2+ 
stores can be pharmacologically identified by their differential inhibition by low 
concentrations of thapsigargin, as a low concentration of thapsigargin can induce 
inhibition of SERCA 2b (Cavallini et al., 1995) whilst SERCA3 needs much higher 
thapsigargin concentrations to be inhibited (Wuytack et al., 1994; Bobe et al., 1994), 
and can also be inhibited specifically by 2,5-di –(t-butyl)-1,4-hydroquinone (TBHQ; 
Enyedi et al., 1992). Other studies have demonstrated that the two SERCA isoforms are 
differentially distributed between two Inositol 1,4,5-trisphosphate (IP3)-dependent Ca
2+ 
stores (Cavallini et al., 1995). This was further supported by immunolabelling studies 
which indicated different subcellular localizations of the two SERCA isoforms (Kovacs et 
al., 1997) and thus the release of Ca2+ from stores depends on the exposure to TBHQ 
or not and on the concentration of thapsigargin (Cavallini et al., 1995). Although 
currently not definitively characterized, the SERCA3-containing acidic stores likely 
represent the platelet lysosome and secretory granules (Lopez et al., 2006; Ruiz et al., 
2004; Sage et al. 2011). In addition to SERCA3, recent work has provided initial 
evidence that the acidic Ca2+ stores also possess an additional secondary-active Ca2+ 
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transporter which utilizes the transmembrane pH gradient to also drive Ca2+ uptake into 
this store (Sage et al., 2011).  
Resting platelets primarily remove Ca2+ across the plasma membrane utilizing a plasma 
membrane Ca2+ ATPase (PMCA; Johansson & Haynes, 1988; Jones et al., 2010).  
Human platelets principally express the PMCA4 isoform, although there is a small 
amount of PMCA1b isoform protein also observed in these cells (Martin et al., 2000). 
Interestingly, immunolabelling studies have found an assymetric distribution of PMCA in 
resting platelets, with much of the PMCA being found in the OCS in the vicinity of the 
DTS (Cutler et al., 1978) – in line with its selective accumulation around the membrane 
complex.   
In addition to the PMCA, platelets have also been shown to contain Na+/Ca2+ exchanger 
(NCX) 3 isoform (Harper et al., 2010; Roberts et al., 2012). Although this transporter 
can remove Ca2+ from the cytosol, it has a much lower affinity for Ca2+ than the PMCA, 
but a much higher transport capacity – because of this the NCX system in platelets is 
thought to play a key role in rapidly removing Ca2+ from the cytosol upon platelet 
activation when [Ca2+]cyt  is raised (Valant et al., 1992; Sage et al., 2013). 
 
   1.5.4 Agonist-evoked rises in [Ca2+]cyt occur via Ca
2+ release and Ca2+ entry  
Upon damage to the blood vessels, platelet agonists such as thrombin and collagen 
evoke platelet activation through triggering intracellular signalling cascades through the 
binding of these agonists to their respective receptors - with collagen activating platelet 
via the activation of glycoprotein VI and integrin α2β1 (Jackson et al., 2003) and thrombin 
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triggering platelet activation via the cleavage of the protease-activated receptor (PAR) 
isoforms PAR1 and PAR4 (Vu et al., 1991; Kahn et al., 1998).  Both of these receptors 
invoke platelet activation through triggering a rise in [Ca2+]cyt through their activation of 
phospholipase C (Figure 8) which catalyses the breakdown of phosphatidylinositol 4,5-
bisphosphate (PIP2) to the second messengers, IP3 and 1,2-diacylglycerol (DAG; 
Rittenhouse and Allen, 1982; Watson et al., 1985). In addition there is evidence that 
platelet activation with both thrombin and the GPVI-specific agonist, collagen-related 
peptide (CRP) leads to the production of another second messenger, nicotinic acid 
adenine dinucleotide phosphate (NAADP: Coxon et al., 2012; Lopez et al., 2006; Sage 
et al., 2011). The agonist-evoked IP3 production elicits Ca
2+ release from the DTS by 
triggering the opening of Ca2+-permeable IP3 receptors (Authi & Crawford, 1985; Brass 
& Joseph, 1985; Sage et al., 2011). In contrast, NAADP production appears to trigger 
Ca2+ release from the acidic Ca2+ stores (Coxon et al., 2012; Lopez et al., 2006; Sage et 
al., 2011), presumably through the two-pore channels, TPCN1/2 (Ruas et al., 2015) 
which have previously been found in the platelet proteome (Burkhart et al.,2012). These 
channels are expressed on the membranes of endosomes and lysosomes where they 
form receptors for nicotinic acid adenine dinucleotide phosphate (NAADP) (Zhu et al., 
2010) 
The Adenosine Triphosphate (ATP)-gated receptor-operated P2X1 channel (MacKenzie 
et al., 1996; Mahaut-Smith et al., 2000) is the simplest one as it elicits a small rise in 
[Ca2+]cyt. Recent studies have found that this channel most likely act as part of an 
autocrine signalling system activated when platelets secrete ATP from their dense 
granules, and which works to reinforce the activation of principal agonists such as 
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collagen and thrombin (Fung et al., 2007; Oury et al., 2001). This pathway appears to 
be particularly important in mediating rapid platelet activation under conditions of high 
shear stress (Hechler et al., 2003). 
In addition to Ca2+ release from intracellular stores, platelets are able to elicit Ca2+ entry 
through the plasma membrane through a number of Ca2+-permeable ion channels (Fig. 
1.8). 
 
Figure 1.8: The major molecular pathways for platelet Ca
2+ 
signalling.  Activation of platelets by 
agonists leads to the production of IP3 and DAG. The IP3 releases the store Ca
2+ 
and STIM1 stimulates 
Orai1 channels for Ca
2+ 
influx (SOCE) while DAG induces non-SOCE through TRPC6 for Ca
2+ 
influx. 
Secondary Ca
2+   
entry occurs by receptor operated Ca
2+ 
channel, Na
+
/Ca
2+
 exchanger and P2X1. In turn 
Ca
2+
removal occurs through SERCAs into the store and to the cell exterior through the plasma membrane 
Ca
2+
 ATPase (PMCAs; figure reproduced from Varga-Szabo et al., (2009)). 
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Perhaps the most important Ca2+ entry pathway is store-operated Ca2+ entry (SOCE). In 
this mechanism, Ca2+ entry is elicited through a store-operated channel when Ca2+ 
levels fall in the intracellular Ca2+ stores. Recent work has identified Orai1 as a principal 
component of the store-operated channel (Braun et al., 2009; Bergmaier et al., 2009). 
Although an Orai1 homomultimer may comprise the store-operated channel, previous 
work had suggested that this channel may also contain channels such as TRPC1 which 
may modulate the Ca2+ signal elicited through this channel (Rosado et al., 2002; 
Brownlow & Sage, 2005). However in contrast to Orai1-deficient mice, TRPC1 knockout 
mice show no obvious deficit in their Ca2+signalling – therefore arguing against this 
channel forming a significant component of the platelet store-operated channel in mice 
(Vargas-Szabo et al., 2009).    
To be activated by store-depletion the store-operated channel requires a signal to be 
sent from the DTS to the plasma-membrane-localised Orai1-containing channel. Recent 
work has identified that the DTS-localised STIM1 protein is able to sense changes in the 
Ca2+ concentration within the intracellular Ca2+ stores in both human and mouse 
platelets (Vargas-Szabo et al., 2008; Misceo et al., 2014; Nakamura et al., 2013; 
Markello et al., 2015), and communicate this to the Orai1-containing channel through 
conformational coupling between the two proteins. Interestingly,                                                                                                                                                                                                                                                                                             
both Orai1- and STIM1-knockout mice showed no obvious bleeding diathesis, but did 
demonstrate reduced platelet aggregate formation under flow (Braun et al., 2009; 
Vargas-Szabo et al., 2008) – suggesting a key role for this channel in mediating 
thrombus formation. 
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Platelets are also known to contain DAG-activated second messenger-operated 
channels such as TRPC3 and TRPC6 (Hassock et al., 2002; Harper et al., 2013; 
Estacion et al., 2006; Onohara et al., 2006). Studies of TRPC6 knockout mice have 
shown that these cells are unable to elicit DAG-mediated Ca2+ entry, yet Ca2+ entry 
through the store-operated channel appears unaffected (Ramanathan et al., 2012). 
Interestingly the store-operated entry appears to be sufficient enough to maintain in vitro 
and in vivo platelet activation suggesting a minimal role of TRPC6 in the initial activation 
of murine platelets (Ramanathan et al., 2012). However, more recent work by Harper et 
al., (2013), has demonstrated a role for the DAG-activated TRPC3 and TRPC6 isoforms 
in eliciting phosphatidylserine exposure in agonist-evoked platelets – suggesting that 
Ca2+ entry through these channels principally affects platelet-mediated activation of the 
coagulation cascade, but not primary haemostatic reactions. 
Lastly, previous work has suggested that the Na+/Ca2+ exchanger may also act as a 
Ca2+ entry mechanism by acting in reverse mode to bring Ca2+ into the platelet when 
cytosolic Na+ levels are raised (Roberts et al., 2012; Harper et al., 2013) – however the 
relative importance of this over the traditional forward mode exchange of this transporter 
is currently unclear (Harper et al., 2009; Sage et al., 2013). Current work suggests that 
the relative importance of reverse mode and forward mode exchange may be different 
for collagen and thrombin  - with reverse mode being elicited by collagen activation of 
platelets (Roberts et al., 2012), whilst in thrombin-stimulated platelet forward mode 
exchange likely dominates (Sage et al.2013). 
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   1.5.5 Maintained Ca2+ rises underlies changes in platelet phenotype 
A rise in the [Ca2+]cyt is a crucial event in platelet activation triggered by agonists 
exposed at the site of any vascular damage. This cytosolic Ca2+ elevation drives a 
variety of signalling processes that end with platelet aggregation leading to thrombus 
formation at the site of vascular damage (Rink and Sage, 1990). Therefore, knowing 
how the platelets initiate and regulate their Ca2+ signalling processes could help us to 
produce new anticoagulant drugs that act by interrupting these signals.   
Ca2+ signals in all cells have two crucial variables which may underlie their ability to 
regulate biological events (Berridge et al., 2000); the amplitude of the change in Ca2+ 
away from resting [Ca2+]cyt and the duration of Ca
2+ rises. A number of previous platelet 
studies have demonstrated that extending the duration of the platelet Ca2+ signal is 
important in mediating a range of transitions in the platelet response (Heemskerk et al., 
2013). Mazzucato et al. (2002) found that when Ca2+ signals were monitored in platelets 
perfused over vWF-coated coverslips, different Ca2+ signalling patterns could be 
observed with different functional effects. Transient Ca2+ signals caused by Ca2+ release 
from the DTS triggered transient platelet adhesion, with platelets detaching after the 
Ca2+ signal had declined towards resting levels. In contrast, when platelets were 
observed to have maintained Ca2+ signals due to autocrine ADP signalling leading to 
Ca2+ entry across the plasma membrane, there was irreversible adhesion and 
aggregate formation.  Similar results were found in vivo studies of thrombus formation in 
rabbits by Van Gestel et al., (2002) – who demonstrated that platelets binding to a 
forming thrombus that maintained their Ca2+ signals formed part of the thrombus, whilst 
platelets in which the Ca2+ signals started to drop off were found to embolise. These 
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results therefore suggest that maintained and synchronous Ca2+ signalling is crucial for 
thrombus formation and growth (Nesbitt et al., 2003). 
A transition in activated platelet function is also known to be important in facilitating 
secondary haemostatic reactions leading to the local activation of the clotting cascade, 
thrombin activation and fibrin formation to help stabilize the primary platelet aggregate 
at the site of vascular injury – as clotting factors require the expression of anionic 
phospholipids to recruit them to the platelet surface. Interestingly, studies have also 
shown that platelets that were found to have prolonged Ca2+ increases were also found 
to facilitate the transition from a proaggregatory, fibrinogen-binding phenotype into a 
procoagulant, phosphatidylserine platelet phenotype (Kulkarni & Jackson, 2004; 
Jackson & Schoenwalder, 2010).  
As can be seen from the above discussion, prolonged Ca2+ signalling plays a role in 
determining the rate and extent of both primary and secondary haemostatic systems 
and thus targeting Ca2+ signalling systems to block prolonged Ca2+ signalling may be 
useful for limiting the extent of unwanted platelet aggregation in heart attacks and 
strokes. Previous studies of agonist-evoked Ca2+ signalling in patients with a delta 
storage pool bleeding disorder has shown that agonist-stimulated release of autocoids 
from dense granules is required to prolong agonist-evoked Ca2+ signals (Lages & 
Weiss, 1999). Thus study goes on to show that secondary stimulation of the platelet 
helps to maintain agonist-evoked Ca2+ signals by further opening Ca2+-permeable ion 
channels in the platelet plasma membrane. This work suggests that dense granule 
secretion is critical to the production of prolonged Ca2+ signals and thus could be the 
underlying cause of the failure to effectively clot in these patients. 
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   1.5.6 Pericellular Ca2+ signalling helps maintain agonist-evoked cytosolic Ca2+ 
signals in human platelets.  
Studies in our lab have demonstrated a role for normal NCX function in regulating the 
rate and extent of dense granule secretion in platelets stimulated in a number of 
different ways (Harper et al., 2009; Harper et al., 2010; Sage et al., 2013). More 
recently, our lab has provided evidence that this appears to be principally related to this 
transporter specifically transporting Ca2+ into the OCS, where it can accumulate and 
recycle back into the platelet through Ca2+-permeable ion channels, facilitating Ca2+-
regulated dense granule secretion (Sage et al., 2013 Knight & Scrutton, 1984). 
Preventing the pericellular Ca2+ rise through preventing Ca2+ efflux from the platelet, 
buffering the Ca2+ accumulation within the pericellular region or blocking Ca2+ re-entry 
through the plasma membrane inhibited thrombin-evoked Ca2+ increases as well as 
reducing dense granule secretion (Sage et al., 2013). 
Analysis of these pericellular Ca2+ rises found that these appeared to originate from a 
specific subdomain of the platelet. Considering the known ultrastructure of the platelet 
and the location of this Ca2+ rise in the pericellular region, this work suggested that the 
membrane complex might provide a suitable structure for creation of this initial 
pericellular Ca2+ accumulation (Sage et al., 2013). Further mathematical analysis of the 
measured Ca2+ fluxes into and out of the platelets further supported the need for the 
membrane complex in mediating the pericellular Ca2+ hotspot (Sage et al., 2013).  
These data therefore suggested that drugs which disrupt this subcellular structure in 
platelet might provide a novel mechanism by which to dampen normal platelet function 
in patients at risk of heart attacks and strokes. This idea is also supported by previous 
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reports about patients with bleeding disorders related to defective platelet membrane 
structure (Canizares et al., 1990; Green et al., 1981; Meiamed et al., 1984; Parker et al., 
1993), including one family where a hereditary abnormality of the membrane complex 
structure was found to be associated with a defect in thrombin-induced Ca2+ signalling 
(Parker et al., 1993). 
    
   1.5.7 Nicergoline prevents pericellular Ca2+ recycling in human platelets 
Previous studies have shown that the known anti-thrombotic drug, nicergoline, has 
different functions at two different concentrations; at low concentration it has a blocking 
effect on the α-adrenoreceptors, while much higher concentrations of this drug are 
needed to inhibit in vivo platelet functions such as platelet activation, aggregation and 
secretion (Lanza et al., 1986; Le Menn et al., 1979). These studies suggested that the 
anti-platelet effect was mediated by nicergoline’s ability to disrupt the cortical 
microtubule ring and thus trigger a redistribution of both the dense tubular system and 
open canalicular systems (Le Menn et al., 1979). Through this effect, it is possible that 
nicergoline disrupts the membrane complex (MC). This is consistent with previous work 
that had shown that the cortical microtubules interact closely with the DTS. (Behnke, 
1967; White, 1972). Therefore the cortical microtubule bundle may provide a method to 
anchor this structure in specific areas of the platelet including at the MC.  
Previous work had identified that the membrane complex might be the site of creation of 
the pericellular Ca2+ accumulation (Sage et al., 2013). Therefore we hypothesised that 
nicergoline might interrupt pericellular Ca2+ recycling and this might be the basis for its 
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ability to block the normal haemostatic functions of platelets (Lanza et al., 1986; Le 
Menn et al., 1979; Walford et al., 2016). In this paper we confirmed that nicergoline can 
disrupt the structure of the cortical microtubule bundle as well as ultrastructure 
localization of the DTS, as observed via fluorescence microscopic observation using 
either a fluorescent taxol derivative or an antibody directed to ER-resident KDEL 
proteins respectively.  When various aspects of platelet Ca2+ signaling were observed in 
the absence of extracellular Ca2+, nicergoline could be observed to significantly reduce 
thrombin-evoked Ca2+ signals caused by an inhibition of pericellular Ca2+ recycling 
(Figure 9; Walford et al., 2016). These effects could however be reversed by preventing 
the reorganization of the cortical microtubule bundle by prior treatment with the 
microtubule-stabilising agen, taxol, prior to nicergoline treatment.  These data therefore 
suggest that nicergoline elicits its effect on pericellullar Ca2+ recycling by triggering a 
microtubule-dependent relocation of the DTS away from the OCS. These results are 
consistent with the hypothesis that the MC is a critical structure in regulating and 
maintaining agonist-evoked cytosolic Ca2+ signals.   
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Figure 1.9:  Pericellular Ca
2+
 recycling and the mechanism of action of nicergoline in human 
platelets. The interaction of the two membranes of the  membrane complex support the primary Ca
2+
 
signalling during platelet  activation by helping to couple Ca
2+
 release from the IP3 receptor to Ca
2+
 efflux 
through the NCX.  This creates an accumulation of Ca
2+   
in the lumen of the OCS – such that it can 
create a concentration gradient driving Ca
2+
 back in the cytosol through the various Ca
2+
-permeable ion 
channels in the plasma membrane. This in turns potentiates Ca
2+
 signalling by potentiating Ca
2+
 release 
and triggering secretion of autocrine signalling molecules from the dense granules.  Addition of 
Nicergoline distorts the microtubule network which holds the DTS in intimate contact with OCS, leading to 
disruption of the close contact of the membranes at the MC, and thus preventing pericellular Ca
2+
 
recycling, thus impairing the creation of  the cytosolic Ca
2+ 
signal (Figure adapted from Walford et al., 
2016). 
 
However this ability to reverse the effect of nicergoline on thrombin-evoked Ca2+ signals 
could not be observed when cells were stimulated with this agonist in the presence of 
extracellular Ca2+. This discrepancy appears to be related to additional off-target effects 
of nicergoline on dense granule secretion when Ca2+ was present in the extracellular 
fluid, as nicergoline-induced inhibition of dense-granule secretion was only found to be 
partially reversed by taxol treatment (Walford et al., 2016).  However our previous 
studies haven’t identified how nicergoline treatment is able to disrupt the cortical 
microtubules, leading to redistribution of the DTS and OCS. Previously we hypothesized 
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that nicergoline might work through either altering the activity of molecular motors 
associated with microtubule motility or via altering the post-translational modification of 
tubulin (Walford et al., 2016).  
In the next section we will review the current understanding of how each of these factors 
alters platelet function. 
 
   1.5.8 Post-translational modification of platelet microtubules 
The function of microtubules is controlled by a variety of post-translational modifications 
(PTMs) such as (poly)glutamylation (Eddé et al., 1990; Alexander et al., 1991; Redeker 
et al., 1992), detyrosination (Arce et al.,1975; Hallak et al., 1977), acetylation 
(L'Hernault and Rosenbaum, 1985; Chu et al., 2011) and (poly)glycylation (Redeker et 
al., 1994). Tubulin subunits within microtubules often show a number of these known 
PTMs suggesting that they could play a role in controlling the functions of these 
microtubules (Szyk et al., 2014). The PTMs of tubulin subunits have been shown to 
regulate the microtubule function through an interaction with microtubule-stabilizing or 
destabilizing proteins helping to alter the rate of microtubule cycling (Chakraborti et al., 
2016). Furthermore these modifications are known to alter the interaction of the 
microtubules with molecular motor proteins such as kinesin and dynein, thus facilitating 
their ability to act as points for cellular transport and force generation (Chakraborti et al., 
2016).  Of the different post-translational modification of microtubules, (de)tyrosination 
and acetylation are the best studied in human platelets. 
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Microtubules can be reversibly acetylated by the action of the N-acetyltransferases   
such as ARD1-NAT1 and the elongator complex, and deacetylated by both the SIRT2 
and HDAC6 enzymes (Hubbert et al., 2002; Janke & Kneussel, 2010). Acetylation is 
found on stable microtubules which do not undergo the cycles of microtubule 
polymerisation and collapse. However acetylation is a consequence of microtubule 
stabilisation and not the cause of this phenomena (Palazzo et al., 2003). However 
acetylation is associated with modulating interaction of microtubules with motor proteins 
such as kinesin and dyneins (Reed et al., 2006; Cai et al., 2009). 
Data has shown that the microtubules that make up the marginal band consist of stable 
and highly polymerized, acetylated and tyrosinated α-tubulin subunits – suggesting the 
presence of both older, static microtubules as well as newer, more dynamic structures 
(Patel-Hett et al., 2008). Upon platelet activation, the marginal band of microtubules is 
subjected to a contraction force towards the centre which is associated with microtubule 
deacetylation by HDAC6 (Sadoul et al., 2012). Further studies with HDAC inhibitors 
have shown that acetylation of microtubules in human platelets can regulate both the 
resting structure of the cortical microtubule bundles, as well as the collagen-mediated 
signalling events which can lead to its reorganisation (Aslan et al., 2013).  These 
studies therefore suggest that acetylation of the microtubules could impact significantly 
on platelet function. 
Detyrosination is the most well-known tubulin modification achieved by removing the 
tyrosine from the C-terminal region by a carboxypeptidase of unknown origin (Hallak et 
al., 1977). Tyrosinated tubulin molecules are known to be used by newly polymerizing 
microtubules, and this tyrosination is used as a marker of newly formed microtubules 
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(Janke & Bullinski, 2011). Similarly detyrosination of tubulin is responsible for 
stabilization of the microtubules (Schulze et al., 1987) as these microtubules are kept 
polymerized without collapse (Janke & Kneussel, 2010). Previous studies in human 
platelets have demonstrated that tyrosinated tubulin molecules are generally found in 
the cortical microtubule bundle, whereas detyrosinated microtubules are found in the 
coiling sections of the microtubules which are responsible for spheration of platelets 
upon agonist-activation (Diagouraga et al., 2014).  
These data therefore suggest the possibility that nicergoline-induced alterations in the 
PTM of microtubules could be the causes of the observed change in the structure of the 
cortical microtubule bundle.  
 
   1.5.9 Molecular motors in human platelets 
In addition to PTMs of microtubules altering their structure, molecular motors such as 
kinesin, dyneins and myosin may play a role in generating active forces to move 
attached cargos (Akhmanova & Hammer, 2010; Reed et al., 2006; Dompierre et al., 
2007) or to deform or remodel the cell (Merdes et al., 1996; Piperno et al., 1987; 
Schatten et al., 1988). A review of the platelet proteome has identified that each of 
these molecular motors are found in human platelets (Sadoul et al., 2012), however 
there are variable amounts of data available regarding their role in regulating normal 
platelet function.  
Myosin is a large ATPase molecule that can hydrolyse ATP releasing energy from the 
high-energy phosphate bond to generate a contractile force that can pull actin over the 
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myosin molecule generating contractile forces.   The force generated by the myosin 
motor has been demonstrated to induce platelet shape change, internal contraction and 
clot retraction (Johnson et al., 2007, Daniel et al., 1984; Cohen et al., 1982; Feghhi et 
al., 2016). Upon platelet activation, constriction of the cortical cytoskeleton results in the 
centralization of platelet secretory granules by this shrinking ring of microtubules and 
actin. This results in the concentration of granules in the middle of the cell thus 
facilitating their exocytosis (White & Burris, 1984). 
In support of this previous studies have demonstrated that myosin plays a role in 
promoting granule secretion (Painter & Ginsberg, 1984; Flaumenhaft, 2003). 
Dynein acts as a microtubule-associated motor which can help to move attached cargo 
along these cytoskeletal elements in a minus-end directed manner (Karki &  Holzbaur, 
1999).  In particular, dyneins have been shown to play a role in controlling endoplasmic 
reticulum positioning and growth within cells (Wózniak et al., 2009), and thus may play a 
role in controlling the distribution of the DTS within the platelet.  Recent work has 
demonstrated that dyneins play a role in maintaining the structure of the cortical 
microtubule ring by counteracting the force exerted by the plus-end directed kinesin 
motors (Diagouraga et al., 2014).  Upon platelet activation, the antagonistic action of the 
microtubule motors is disrupted with kinesin activity reduced and dynein function 
upregulated leading to elongation of the microtubule bundle (Diagouraga et al., 2014).   
Previous studies has defined that kinesins function as molecular motor proteins that use 
ATP hydrolysis to move anchored cargo generally towards the plus ends of the 
microtubules (Wells et al., 1999). This movement facilitates the position and 
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transportation of organelles and secretory granules inside the cell (Marx et al., 2009). 
Previous work in platelets have demonstrated a role for kinesins in preventing dynein-
induced coiling of the cortical microtubules, with pre-treatment with the kinesin-inhibitor, 
aurintricarboxylic acid (ATA; Hopkins et al., 2010), inducing spontaneous coiling of the 
cortical microtubules (Diagouraga et al, 2014). Interestingly previous studies have also 
shown that ATA is known to possess anti-thrombotic capacities in in vivo models of 
thrombus formation (Phillips et al., 1988; Owens & Holme, 1996; Azzam et al. 1996, 
Takiguichi et al., 1996).  
 
  1.6 Aims and objectives of the project 
Our hypothesis is that nicergoline works by either altering the efficiency of the molecular 
motors associated with microtubule motility (such as myosin, kinesin and dynein), or via 
its ability to alter post translational modifications of tubulin such as changing the 
acetylation or tyrosination state of microtubules. In this project we will examine how 
inhibition of histone deacetylases, myosin, kinesin and dynein affects agonist-evoked 
Ca2+ signals as well as the change in function of human platelets to examine whether 
these replicate the effects of nicergoline, or whether treatment concurrently with 
nicergoline could reverse the effect of this drug.  Through this approach, we aim to 
identify the molecular mechanism by which nicergoline inhibits the cortical microtubule 
structure, DTS distribution and platelet Ca2+ signalling.      
In addition, we hypothesized that nicergoline will inhibit Ca2+ signalling in CD34+-derived 
human megakaryocytes in a similar manner to that found in human platelets.  We 
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therefore aimed to assess the effect of nicergoline on thrombin-evoked Ca2+ signalling in 
these cells and evaluate their similarity to that found in human platelets.  If verified, it 
was hoped that CD34+-derived human megakaryocytes may be used as a model 
system in which to identify the molecular target of nicergoline in human platelets in the 
future. 
 
 2. Materials and Methods 
  2.1 Materials 
Fura-2/AM was from TEFlabs Inc. (Austin,TX). Thrombin was from Merck Chemicals 
(Nottingham, U.K.). Apyrase, adenosine triphosphate, aurin tricarboxcylic acid, DNAse I, 
5-5’-Dimethyl-BAPTA/AM, blebbistatin, trichostatin A, poly-L-lysine solution, Hoechst 
33342 and the Luciferin-luciferase ATP assay kit were from Sigma Aldrich (Gillingham, 
UK). StemSpan™ SFEM-II media and StemSpan™ CC100 cytokine cocktail were from 
Stemcell technologies (Cambridge, UK). Recombinant human thrombopoietin (TPO), 
Interleukin 6 (IL-6), Interleukin 9 (IL-9) and Stem Cell Factor (SCF) were obtained from 
PeproTech EC Ltd. (London, UK). Nunc™ 8-well Lab-Tek™ II chambered coverglass 
were from Fisher Scientific UK (Loughborough, UK). Fluo-5N/AM, Fluo-4 
pentapotassium salt, Tubulin Tracker and Rhod-5N tripotassium salt were from Life 
Technologies Ltd (Paisley, UK). Human CD34+ cells from bone marrow were obtained 
from Lonza (Blackley, UK). Fetal calf serum was from Labtech international Ltd. 
(Lichfield, UK). Nicergoline and ciliobrevin A were from Tocris Bioscience (Bristol, UK). 
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Phalloidin iFluor555 and anti-KDEL antibody were from Abcam (Cambridge, UK). All 
other reagents were of analytical grade. 
  
  2.2 Methods for human platelet experiments 
   2.2.1 Platelet preparation 
All experiments were approved by Keele University Research Ethics Committee, and 
were conducted in accordance with the Declaration of Helsinki. Blood was taken with 
informed, written consent from healthy, drug-free volunteers by venepuncture from the 
antecubital fossa. 5 mL whole blood was mixed with 1 mL acid citrate dextrose (ACD) 
anticoagulant (85 mM sodium citrate, 78 mM citric acid, and 111 mM D-glucose) and 
centrifuged for 8 min at 700 g. The platelet-rich plasma (PRP) was then collected and 
treated with 100 µM aspirin and 0.1 U/mL apyrase.  
 
   2.2.2 Monitoring platelet cytosolic Ca2+ concentration ([Ca2+]cyt) 
PRP was incubated with 2.5 μM Fura-2/AM for 45 mins at 37°C. Platelets were then 
collected by centrifugation at 350 g for 20 min. The cells were then resuspended in 
Hepes-buffered saline [HBS; 145 mM NaCl, 10 mM Hepes (N-2-hydroxyethylpiperazine-
N-2-ethanesulphonic acid), 10 mM D-glucose, 5 mM KCl, 1 mM MgSO4, pH 7,45], which 
was supplemented daily by addition of 0.1% [w/v] bovine serum albumin, 200 µM CaCl2, 
0.1 U/mL apyrase and 10 mM glucose (supplemented HBS). Fluorescence readings 
were recorded using a Cairn Research Spectrophotometer (Cairn Research, 
Faversham, U.K.) from 1.2 mL aliquots of washed human platelet suspensions that 
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were magnetically stirred and held at 37°C. Fluorescence was recorded when cells 
were excited with 340 nm and 380 nm light, and emission wavelengths were collected 
between 470-550 nm. Readings were routinely corrected for autofluorescence by 
subtraction of 340 and 380 nm values recorded from a cuvette containing HBS alone. 
Calibration of fluorescence readings was performed by determing the 340 and 380 nm 
values obtained from platelets samples from both drug- and DMSO-containing platelet 
samples in which the dye had been released from the cell by lysis by addition of a final 
concentration of 0.02% [v/v] Triton X-100.  Ca2+ was then raised to saturating levels by 
addition of 3 mM CaCl2. Ca
2+ was then removed from the extracellular medium by 
sequential addition of 15 mM EGTA and 30 mM Tris until there was no further 
decrement in the 340 nm values – indicating effective buffering of all extracellular Ca2+. 
The corrected 340/380 nm fluorescence ratio of all experimental runs was then 
calculated and calibrated into [Ca2+]cyt and using the method of  Grynkiewicz et al., 
(1985). 
 
   2.2.3 Quantification of agonist-induced cytosolic Ca2+ rises  
Quantitative changes of thrombin-evoked intracellular Ca2+ concentration were 
calculated by integrating the difference in fluorescence readings obtained from basal 
and readings of 3.5 min duration after thrombin stimulation. 
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   2.2.4 Monitoring agonist-evoked rises in platelet extracellular Ca2+ 
concentration ([Ca2+]ext) 
This was conducted in accordance with our previously published methodology (Sage et 
al., 2013). PRP obtained from fresh human blood was centrifuged at 350g for 20 
minutes and the platelet pellet obtained was then resuspended in supplemented HBS to 
produce a cell density of 2x108 cells/mL. Samples of 1.2 mL were used at 37°C under 
continuous magnetic stirring to monitor the [Ca2+]ext  after the addition of 2.5 µM Fluo-4 
K+ salt immediately prior to the start of experiment. A Cairn Research 
Spectrophotometer was used to record fluorescence at 480 nm excitation wavelength 
and 500-550 nm emission wavelengths. Thrombin-evoked rises in [Ca2+]ext were then 
quantified by the integration of the readings of fluorescence changes from basal with 
respect to time for 3.5 minutes after the addition of thrombin.   
 
   2.2.5 Monitoring platelet intracellular store Ca2+ concentration ([Ca2+]st) 
This was conducted in accordance with our previously published methodology (Sage et 
al., 2011). PRP was mixed with 500 nM Fluo-5N/AM at and incubated for 2 hours at 
37°C. Platelets were then extracted from plasma by centrifugation at 350 g for 20 
minutes and resuspended in supplemented HBS to a density of 2x108 cells/mL.  
1.2 mL of platelet suspension was used at 37°C under continuous magnetic stirring to 
study the changes in [Ca2+]st. Changes in Fluo-5N fluorescence were recorded at 485 
nm excitation and 515 nm emission wavelengths using a Cairn Research 
Spectrophotometer. Readings were then corrected for autofluorescence recorded by 
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measuring fluorescence in a sample of HBS containing DMSO or the drug of interest 
alone. Agonist evoked changes in [Ca2+]st were quantified by the integration of the 
changes in fluorescence signal records from basal with respect to time for 3.5 mins after 
agonist addition. 
 
   2.2.6 Monitoring platelet shape change by light transmission aggregometry  
Washed human platelet suspensions were prepared by centrifuging PRP at 350 g for 20 
minutes. Platelets were then resuspended in supplemented HBS to a density of 2x108 
cells/mL. Samples were then pre-incubated with the drug to be tested at 37°C under 
continuous magnetic stirring. 1 mM EGTA was added immediately prior to the 
experiment. 450 µL of washed platelet suspension was added to the cuvette, and 
diluted with 50 µL of supplemented HBS containing EGTA and the same concentration 
of drug or DMSO to ensure light transmission changes stayed within the range of the 
instrument. Cells were held at 37°C under continuous magnetic stirring in a dual 
channel Chrono-Log light transmission aggregometer (Labmedics, Oxfordshire, UK). 
Changes in light transmission were calibrated by comparison against an aggregometry 
cuvette containing supplemented HBS alone. 
 
   2.2.7 Monitoring platelet aggregation by light transmission aggregometry 
Washed human platelet suspensions were prepared by centrifuging PRP at 350 g for 20 
minutes. Platelets were then resuspended in supplemented HBS to a density of 2x108 
cells/mL. Samples were then pre-incubated with the drug to be tested at 37°C under 
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continuous magnetic stirring. The extracellular Ca2+ concentration was then raised to 1 
mM immediately prior to the experiments. 500 µL of drug-treated washed platelet 
suspension was added to the cuvette. Cells were held at 37°C under continuous 
magnetic stirring in a dual channel Chrono-Log light transmission aggregometer 
(Labmedics, Oxfordshire, UK). Changes in light transmission were calibrated to % 
maximum aggregation by comparison against an aggregometry cuvette containing 
supplemented HBS alone. 
 
   2.2.8 Monitoring platelet dense granule secretion  
Washed human platelets suspensions were prepared by centrifuging PRP at 350 g for 
20 minutes. Platelets were then resuspended in supplemented HBS to a density of 
2x108 cells/mL. Washed platelets were then incubated at 37°C under continuous stirring 
with either 30 µM aurin tricarboxylic acid or an equivalent volume of DMSO for 10 
minutes at 37°C under continuous magnetic stirring. EGTA was added to cells at 1mM 
final concentration prior to the start of experiment. 100 µL of each treated platelet 
sample was then transferred to a 96-well microtiter plate and 10 % [v/v] Luciferin 
luciferase assay mix was added immediately before running the experiment. 
Luminescence readings were measured in a BioTek Synergy 2 microplate reader. The 
microplates were held at 37°C and luminescence readings were made prior to thrombin 
addition (L0) and immediately after addition of 0.5 U/mL thrombin (L). All samples were 
normalized to a maximum ATP reading obtained by recording luminescence after the 
addition of 10µM ATP to each well at the end of each run (Lmax).  
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The percentage of maximum luminescence was obtained using the following formula: 
                           (
     
       
) 
 
   2.2.9 Measurement of fixed platelet F-actin content  
Washed human platelet suspensions were prepared by centrifuging PRP at 350 g for 20 
minutes. Platelets were then resuspended in supplemented HBS to a density of 2x108 
cells/mL. 1.5 mL samples were incubated with a final concentration of either 30 µM 
aurin tricarboxylic acid (ATA) or an equivalent volume of DMSO for 10 minutes at 37°C 
under continuous magnetic stirring. EGTA was then added at a final concentration of 
1mM. 0.5 mL of the resting platelet sample was then fixed by addition of 3% [w/v] 
formaldehyde. The remaining 1 mL sample was stimulated with 0.5 U/mL thrombin for 1 
minute at 37°C under stirring. After this another 0.5 mL sample was fixed by the addition 
of 3% [w/v] formaldehyde. Cells were stored at 4°C until the day of experiment. Fixed 
samples were treated in line with previously published studies (Rosado et al., 2000). 
Fixed platelet samples were centrifuged for 1 minute at 8700 g, the supernatant 
removed and the fixed platelet pellet was resuspended in PBS containing 1 mg/mL 
bovine serum albumin (BSA) and 0.1% Triton X-100 to permeabilise the platelet plasma 
membrane, and incubated for 10 minutes at room temperature. The platelet suspension 
was then centrifuged again for 1 minute at 8700 g and the pellet resuspended in PBS 
containing 1 mg/mL BSA and 1 µM iFluor555-phalloidin and incubated in the dark at 
room temperature for 30 minutes. Cells were finally recollected by centrifugation for 1 
minute at 8700 g, and resuspended in PBS containing 1mg/mL BSA. Aliquots of 100 µL 
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of each sample were loaded into 96-well microtiter plate in triplicate. Cells were 
examined for F-actin content in both the resting and thrombin-stimulated state using a 
BioTek Synergy 2 microplate reader and fluorescence was recorded at 540 nm 
excitation wavelength and 590 nm emission wavelength. Thrombin-evoked changes in 
F-actin content were calculated by subtracting the fluorescence measurement taken 
from the resting sample from that obtained from the thrombin-stimulated sample. The 
mean of the triplicate of each sample was then calculated and used as 1 independent 
sample (n).  
 
   2.2.10 Single cell imaging of agonist evoked [Ca2+]ext changes in live human 
platelets 
Experiments were performed with our previously published protocol (Sage et al., 2011). 
Washed human platelet suspensions were prepared by centrifuging PRP at 350 g for 20 
minutes. Platelets were then resuspended in supplemented HBS to a cell density of 
2x108 cells/mL. Washed platelet samples were then preincubated with either 30 µM 
ATA or an equivalent volume of DMSO for 10 minutes at 37°C under continuous 
magnetic stirring. Samples were treated with 1 mM EGTA. Cell suspensions were then 
loaded onto poly-L-lysine-coated chambered coverslides and allowed to settle for 5 
minutes prior to imaging. 10 µM Fluo-4 salt was then added and mixed gently 
immediately prior to the experiment. Cells were imaged before and for 5 minutes after 
addition of 0.5 U/mL thrombin using Fluoview FV1200s laser-scanning confocal 
microscope (Olympus, UK) with a PLAPON 60x oil immersion objective. Cells were 
excited with 473 nm light and emission was collected at 490-520 nm.  
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  2.3   Methods for human megakaryocyte cell experiments 
 
   2.3.1 In vitro culture of CD34+ cells into human megakaryocytes 
Human CD34+ cells were obtained from Lonza (Slough, UK).  Upon arrival, CD34+ cells 
were cultured in SFEM-II media containing StemSpan™ CC100 cytokine cocktail 
SFEM-II expansion medium for 7 days at 37°C in 5% CO2 and 20% O2 as per the 
manufacturer’s instructions. Cells were then aliquoted and frozen in liquid nitrogen. 
CD34+ cell aliquots were revived as per the manufacturers instruction and resuspended 
into SFEM-II media supplemented with 30 ng/mL TPO, 7.5 ng/mL IL-6, 13.5 ng/mL IL-9 
and 1 ng/mL SCF, according to the method of Pineault et al., (2013). Cells were plated 
at between 2-5 x 105 cells/mL into the central wells of a 24-well tissue culture plate and 
incubated at 37  C in a humidified atmosphere containing 5  CO2 and 20% O2 for up to 
14 days.  
 
   2.3.2 Assessment of megakaryocyte development from CD34+ cells 
Cells were examined by light microscopy (Days 2,7 and 11) throughout the culture to 
track changes in cell proliferation and colony formation. Cell viability was checked on 
day 7-9 of the culture using trypan blue.  
Megakaryocyte cellular structure was also examined by fluorescent microscopy on days 
2 and 7 of the megakaryocyte culture. On the day of preparation, Cells were incubated 
with 1 µM Fluo-5N/AM for 2 hours and 5 μg/mL Hoechst 33342 for 1 hour at 37°C under 
5% CO2 and 20% O2. Cells were then collected by centrifugation at 228 x g for 10 
minutes. The supernatant was discarded and the cell pellet was then resuspended into 
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supplemented HBS containing 0.1% [w/v] bovine serum albumin, 200 µM CaCl2, 0.1 
U/mL apyrase and 10 mM glucose to a final density of 1x105 cells/mL. Poly-L-lysine-
coated Nunc chambered coverglass was washed with supplemented HBS before cell 
addition. 200 μL of the cell suspension was then added to the well and cells were 
allowed to settle for 30 minutes at room temperature. Immediately prior to imaging, 10 
µM Rhod-5N tripotassium salt was added to the suspension. Cellular fluorescence was 
then examined using a Fluoview FV1200 laser-scanning confocal microscope 
(Olympus, UK) with a PLAPON 60x oil immersion objective. Cells were excited with 405 
nm (Hoechst 33342), 473 nm (Fluo-5N) and 543 nm (Rhod-5N) light and emission was 
collected at 460-490 nm, 490-520 nm and 590-620nm respectively. 
 
   2.3.3 Single cell examination of cell-surface markers of megakaryocyte 
development in CD34+ cell culture 
Megakaryocyte cultures were fixed on day 2 or day 7-9 by addition of 3% [w/v] 
formaldehyde and stored at 4°C until use. Megakaryocyte samples were centrifuged at 
6000 x g for 1 minute, and the pellet resuspended into 100 uL of PBS containing 1 
mg/mL BSA and a 1:100 dilution of APC-labelled CD41a antibodies and FITC-labelled 
CD42b antibodies and incubated at room temperature for 30 min. Cells were recollected 
by centrifugation and finally resuspended in PBS containing 1 mg/mL BSA. Cells were 
loaded onto Poly-L-lysine Nunc Chambered coverslips and imaged using a Fluoview 
FV1200 laser-scanning confocal microscope (Olympus, UK) with a PLAPON 60x oil 
immersion objective. Cells were excited with 473 nm (FITC) and 543 nm (APC) light and 
emission was collected at 490-520 nm and 590-620 nm respectively.  
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   2.3.4 Single cell imaging of thrombin-evoked intracellular Ca2+ and extracellular     
Ca2+ signalling in nicergoline treated CD34+-derived megakaryocytes 
A 1 mL sample of CD34+-derived cells on day 9 of the culture was incubated with 5 µM 
Fluo-2/AM and 5 µg/mL Hoechst 33342 dyes. After 1 hour incubation at 37ºC, 0.1 U/mL 
apyrase was added to the sample and sample centrifuged at 8400 g for 1 minute. 
Supernatant was removed and pellet resuspended with 250 µL of supplemented HBS. 5 
µM Rhod-5N dye and 1 mM CaCl2 were then added. Cells were loaded onto a poly-L-
lysine coated chambered coverslide after washing with 200 µl HBS and left for 30 
minutes at room temperature to attach. 100 µM Nicergoline or an equivalent volume of 
DMSO was added to samples and they were incubated for 5 minutes at room 
temperature. Cells were imaged using a Fluoview FV1200 laser-scanning confocal 
microscope (Olympus, UK) with a PLAPON 60x oil immersion objective. Cells were 
excited with 405 nm (Hoechst 33342), 473 nm (Fluo-2) and 543 nm (Rhod-5N) light and 
emission was collected at 460-490 nm, 490-520 nm and 590-620nm, respectively.    
 
   2.3.5 Single cell imaging of the effect of nicergoline on intracellular Ca2+ stores 
in CD34+-derived cultured human megakaryocytes  
A 1 mL cell sample was taken on day 7 of megakaryocyte culture. CD34+-derived cells 
were then incubated with 5 μg/mL Hoechst 33342 and 1 μM Fluo-5N dyes and the 
sample was incubated for two hours at 37°C under 5% CO2 and 20% O2. After 
incubation, 200 µl of sample was loaded onto poly-L-lysine-coated chambered 
coverslides after washing the slide with 200 µl HBS and left for 20 minute at room 
temperature to allow the cells to attach. The cell sample was mixed with 200 µl of 
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supplemented HBS containing 1 mM CaCl2 and 5 μM Rhod-5N salt. Cells were then 
imaged before and after treatment with 100 μM Nicergoline. Imaging was done using a 
Fluoview FV1200 laser-scanning confocal microscope (Olympus, UK) with a PLAPON 
60x oil immersion objective. Cells were excited with 405 nm (Hoechst 33342), 473 nm 
(Fluo-5N) and 543 nm (Rhod-5N) light and emission was collected at 460-490 nm, 490-
520 nm and 590-620nm respectively.  
 
   2.3.6 Microplate reader based measurements of agonist-evoked Ca2+ signals in 
nicergoline treated CD34+-derived cultured human megakaryocytes 
On day 7-9 of the culture cells were incubatd with 2.5 µM Fura-2/AM for 45 minute at 
37°C. Cells were then spun at 228 g for 10 minutes, and resuspended in supplemented 
HBS to a final cell density of 5x104 cells/mL. Cells were treated with either 100 µM 
nicergoline or an equivalent volume of its vehicle, DMSO, and incubated at 37°C under 
continuous magnetic stirring for 10 minutes. Cells were then transferred into a 96-well 
microplate. Extracellular Ca2+ was then either raised to 1 mM or chelated by addition of 
1 mM EGTA.  Cells were stimulated with 0.5 U/mL thrombin and fluorescence was 
recorded using a BioTek Synergy 2 microplate reader using a 360 nm excitation 
wavelength filter and collected using a 440 nm emission filter. The recorded value of 
basal fluorescence was recorded before thrombin addition and a maximal fluorescence 
value was obtained after treatment of each sample with 10% Triton at the end of each 
run. Changes in [Ca2+]cyt was quantified by the integration of the change in fluorescence 
records from basal with respect to time for 5 minutes after thrombin addition. 
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  2.4 Statistical analysis 
Values obtained are referred to as the mean ± standard error of the mean of the number 
of independent observations (n) indicated. Student’s paired t-test was used in 
experiments in which two samples were directly compared. When three or more 
samples were compared a one-way ANOVA Test was initially used before a post hoc 
Tukey Test was used to determine statistical significance. 
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 3. Results 
Previous work in our lab has shown that nicergoline inhibits agonist-evoked platelet 
Ca2+ signalling and dense granule secretion due to disruption of the cortical microtubule 
bundle. This effect is likely due to the disruption of the membrane complex due to the 
dissociation of the DTS from the OCS (Walford et al., 2016). This uncoupling of the 
intracellular Ca2+ stores from the OCS therefore reduces the efficiency of Ca2+ released 
from the intracellular stores being removed into the pericellular space enclosed within 
the OCS. This reduces the pericellular Ca2+ accumulation and prevents the creation of a 
concentration gradient to allow the Ca2+ to recycle back into the platelet which would 
otherwise maintain the agonist-evoked rises in the cytosolic Ca2+ concentration at 
higher levels. 
Therefore in this project we aim to understand how nicergoline elicits a reorganisation of 
the microtubule network and its effect on agonist evoked platelet Ca2+ signalling.  
 
  3.1 Investigating the effect of trichostatin A, an inhibitor of microtubule 
deacetylation, on agonist-evoked human platelet function 
Tubulin is subject to a wide range of different post-translational modifications which can 
significantly alter its structure and function within cells (Song & Brady, 2015). Recent 
studies have shown that the cortical microtubule bundle of resting platelets is highly 
acetylated, and this is removed by the histone deacetylase (HDAC), HDAC6, upon 
platelet activation (Sadoul et al., 2012). Furthermore, these authors found that 
trichostatin A, a selective class I and II mammalian HDAC Inhibitor (Vanhaecke et al., 
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2004) was capable of inhibiting tubulin deacetylation during platelet stimulation (Sadoul 
et al., 2012). Treatment with this histone deacetylase inhibitor can alter the structure of 
the cortical microtubule ring in resting platelets, suggesting the potential for it to have a 
similar effect to nicergoline (Aslan et al., 2013). In addition, HDAC inhibitors were found 
to alter downstream signalling pathways and the kinetics of the spreading response of 
activated platelets (Aslan et al., 2013). These data suggest that alterations in the 
function of these enzymes could play a role in controlling the cellular architecture of 
platelets. Due to this potential effect of HDAC inhibitors on cortical microtubule 
structure, experiments were performed to examine whether treatment of platelets with 
the HDAC inhibitor, trichostatin A (TSA) can either mimic or modulate the inhibitory 
effect of nicergoline on platelet Ca2+ signals and other platelet functional responses.  
Our previous studies demonstrated that the effect of nicergoline on detaching the DTS 
from the OCS in a microtubule-dependent manner could be observed specifically in the 
absence of extracellular Ca2+ (Walford et al., 2016). However in the presence of 
extracellular Ca2+, additional effects of nicergoline could be observed on blocking dense 
granule secretion through a microtubule-independent effect (Walford et al., 2016). 
Therefore to allow us to isolate the microtubule-dependent effect of nicergoline we first 
investigated the effect of TSA on Ca2+ signals elicited in the absence of extracellular 
Ca2+. 
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   3.1.1 Trichostatin A elicited no significant effect on thrombin-evoked cytosolic 
Ca2+ signalling elicited in the absence of extracellular Ca2+ in human platelets 
Fura-2-loaded human platelets were pretreated with either 10 µM TSA, or an equivalent 
volume of its vehicle (DMSO) for 30 minutes, and then further treated with either 100 
µM nicergoline or an equivalent volume of DMSO for a further 10 minutes at 37°C under 
continuous magnetic stirring. Experiments were performed with this sequential drug 
treatment regime to examine whether prior inhibition of HDAC could prevent or mimic 
the effects of nicergoline on thrombin-evoked platelet responses. Pretreatment of 
control cells with TSA had no significant effect on thrombin-evoked rises in cytosolic 
Ca2+ concentration ([Ca2+]cyt; 104.9 ± 5.0% of control; n = 6, P > 0.05, Fig 3.1). Attempts 
to characterize the effect of TSA on the actions of nicergoline failed due to a failure of 
the positive control experiments. This appeared to be due to an effect of this batch of 
nicergoline not becoming fully solubilized by the magnetic stirring during the 
preincubation period, leading to artifacts in the Fura-2 traces that were not observed 
during the initial study (Data not shown; Walford et al., 2016).  
 
   3.1.2 Trichostatin A cannot reverse the effect of nicergoline on thrombin-evoked 
Ca2+ removal into the extracellular fluid in human platelets 
To confirm these initial findings further experiments were conducted to examine whether 
TSA could mimic, or modulate, the effects of nicergoline on thrombin-evoked Ca2+ 
removal from platelets stimulated in the absence of extracellular Ca2+.  Washed human 
platelets were sequentially treated with 10 µM TSA (or DMSO) for 30 minutes, and 100 
µM nicergoline (or DMSO) for further 10 minutes at 37°C under continuous magnetic 
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stirring.  Pretreatment with just TSA had no significant effect on thrombin-evoked rises 
in [Ca2+]ext compared to double DMSO-treated cells (89.9 ± 6.9% of double DMSO-  
 
 
 
 
 
 
 
 
 
Fig. 3.1 Trichostatin A elicited no significant effect on thrombin-evoked cytosolic Ca
2+
 signalling 
elicited in the absence of extracellular Ca
2+
 in human platelets. Fura-2-loaded human platelets were 
pretreated with either 10 µM TSA (B) or an equivalent volume of its vehicle, DMSO (A) for 30 minutes at 
37°C under continuous magnetic stirring. Extracellular Ca
2+
 was chelated with 1 mM EGTA at the 
beginning of the experiment followed 1 minute later by the addition of 0.5 U/mL thrombin. 
 
treated cells, n = 6, P > 0.05; Fig. 3.2C). In contrast, nicergoline treatment significantly 
reduced thrombin-evoked rises in [Ca2+]ext to 52.3 ± 2.4 % of double DMSO-treated cells 
(n = 6, P < 0.05, Fig. 3.2B), which was consistent with our previous findings (Walford et 
al., 2016). When platelets were pre-treated with TSA followed by nicergoline, there was 
still a significant inhibition compared to double DMSO-treated cells (62.9 ± 7.7 %; P < 
0.05; Fig. 3.2D) as well as compared to cells treated with TSA alone (P < 0.05).  
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   3.1.3 TSA has no effect on thrombin-evoked shape change in control-or 
nicergoline-treated platelets. 
Further experiments looked to confirm whether these effects on thrombin-evoked Ca2+ 
signalling correlated with changes in platelet functionality.  Experiments examined the 
effect of sequential treatment with either TSA or nicergoline alone, or with both 
compounds on platelet shape change and aggregation.  As can be seen in Fig. 3.3, 
nicergoline treatment alone significantly inhibited both the maximum shape change 
observed (2.5 ± 0.5% of maximum light transmittance; n = 10; P < 0.05) and the time to 
peak of that shape change (25.9 ± 9.0 s; P < 0.05) when compared to cells treated with 
DMSO at both addition points (12.1 ± 1.2% and 12.6 ± 2.5 s respectively; n = 10).  In 
contrast pre-treatment with TSA alone had no significant effect on the shape change 
response when compared to DMSO-treated control cells (10.8 ± 2.2% and 11.9 ± 1.9 s 
respectively; n = 10). The inhibitory effect of nicergoline treatment was not significantly 
modified by prior treatment with TSA as cells treated with both compounds 
demonstrated both a similar inhibition of the maximum shape change response (2.7 ± 
0.5% of maximum transmittance; n = 10) and the time-to-peak of this responses (29.6 ± 
10.2 s) when compared to nicergoline-treated cells (P > 0.05). Statistical analysis 
demonstrated that these TSA and nicergoline-pretreated cells still demonstrated a 
significantly inhibited response when compared to both untreated control cells and cells 
treated with TSA alone (both P < 0.05). 
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Fig. 3.2: Trichostatin A cannot reverse the effect of nicergoline on thrombin-evoked Ca
2+
 
signalling in human platelets. Fura-2-loaded human platelets were resuspended in supplemented HBS.  
Cells were initially pre-treated with either 10 µM TSA or an equal volume of DMSO for 30 minutes at 
37°C.  This was then followed by an additional 10 minutes incubation with either 100 µM nicergoline or an 
equal volume of DMSO under the same conditions.  2.5 µM Fluo-4 salt was added immediately prior to 
the start of the experiment. Extracellular Ca
2+
 was chelated with 1 mM EGTA at the beginning of the 
experiment followed 1 minute later by the addition of 0.5 U/mL thrombin. 
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   3.1.4 Trichostatin A has no effect on thrombin-evoked platelet aggregation in 
control- and nicergoline-treated platelets. 
Additional experiments examined the effect of these compounds on platelet 
aggregation. As shown in Fig. 3.4, control cells treated with DMSO at both additions 
had a rapid onset of aggregation response (latency = 38.4 ± 9.8 s after thrombin 
addition; n = 5) which lead to near maximal aggregation (82.0 ± 4.7%; n = 5). 
Pretreatment with TSA alone had no significant effect on the maximum extent of 
aggregation observed (81.2 ± 5.2%; n = 5, P > 0.05). The latency of the aggregation 
response was slightly faster in TSA-treated cells compared to control cells, consistent 
with previous findings that HDAC inhibition may facilitate a faster platelet response 
(Sadoul et al. 2012), although this did not reach significance in this study (31.4 ± 1.7 s; 
n =  5, P > 0.05). In contrast, nicergoline treatment alone significantly slowed the latency 
of the aggregation response in thrombin-stimulated platelets (104.6 ± 17.6 s; n = 5, P < 
0.05), although it had no significant extent on the maximum extent of platelet 
aggregation (74.0 ± 5.1%; n = 5, P > 0.05). This effect of nicergoline on the latency of 
the aggregatory response was not significantly modified by prior treatment with TSA, as 
platelets treated with both compounds still had a significantly prolonged latency (99.4 ± 
8.4 s; n = 5, P < 0.05 to both control cells and TSA-treated cells alone).  These cells 
also had a similar aggregatory response to control cells (78.0 ± 6.1%; n = 5, P > 0.05 to 
all other treatments).   
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Fig. 3.3: TSA induced no effect on thrombin-evoked shape change in human platelets. Washed 
platelet samples were incubated at 37°C with either 10 µM TSA (B) or an equal volume of DMSO (A) for 
30 minute at 37°C.  This was then followed by a further 10 minute incubation under the same conditions 
with either 100 µM Nicergoline or an equal volume of DMSO (A,B). Extracellular Ca
2+
 was chelated by 
addition of 1mM EGTA just before the start of the experiment. Cells were then stimulated 2 minutes later 
with 0.5 U/mL thrombin. 
 
These results suggested that prevention of HDAC-mediated microtubule deacetylation 
by pretreatment with TSA exerted no effect on platelet Ca2+ signalling and function, and 
was unable to reverse the inhibitory effect of nicergoline. These data therefore suggest 
that nicergoline does not exert its effect on human platelets through altering the 
acetylation state of the cortical microtubule bundle. 
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Fig 3.4: TSA has no effect on thrombin-evoked aggregation in control- and nicergoline-treated 
human platelets. Washed human platelets resuspended in supplemented HBS were incubated with 
either 10 µM TSA (B) or an equal volume of DMSO (A) for 30 minute followed by a further 10 minutes 
incubation with either 100 µM nicergoline or an equal volume of DMSO (A,B) at 37ºC. 1 M CaCl2 was then 
added prior to the start of the experiment. Cells were then monitored and activated after 2 minutes with 
0.5 U/mL thrombin. 
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  3.2 Investigating the effect of blebbistatin, an inhibitor of the myosin motor 
protein, on thrombin-evoked human platelet function 
Another mechanism by which nicergoline could alter the structure of the cortical 
microtubule bundle is through altering the activity of motor proteins which control the 
structure of the cortical cytoskeleton. The force generated by the myosin motor has 
been demonstrated to induce platelet shape change, internal contraction, granule 
secretion, and clot retraction (Johnson et al., 2007; Daniel et al., 1984; Cohen et al., 
1982; White & Burris, 1984; Painter & Ginsberg, 1984; Flaumenhaft, 2003). If 
nicergoline alters the activation of myosin then this might explain the change in platelet 
structure and granule secretion observed upon nicergoline treatment (Walford et al., 
2016). Experiments were therefore performed to examine whether the myosin inhibitor, 
blebbistatin, can mimic or modulate the effect of nicergoline on thrombin-evoked Ca2+ 
signalling.  
Blebbistatin is a highly selective myosin II inhibitor. It possesses a powerful inhibitory 
effect due to its ability to bind with high affinity to the myosin-ADP-Pi complex, thereby 
blocking myosin activity through interfering with the phosphate release process 
preventing rigid actomyosin cross-linking (Kovacs et al., 2004). Previous studies have 
demonstrated that blebbistatin is able to block platelet shape change, clot retraction and 
internal contraction at doses between 10-100 µM (Johnson et al., 2007; Suzuki-Inoue et 
al., 2007).   
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   3.2.1 Blebbistatin abolishes thrombin-evoked shape change in human platelets. 
Myosin has previously been shown to be essential for agonist-evoked shape change in 
human platelets (Paul et al., 1999). To ensure that blebbistatin was functional, we 
examined the effect of 30 µM blebbistatin on thrombin-evoked shape change. As shown 
in Fig. 3.5, pretreatment with 30 µM blebbistatin for 2 minutes at 37°C completely 
abolished any thrombin-evoked shape change observed in all 6 experiments performed.  
In contrast a clear shape change averaging a light transmittance decrease of 9.4 ± 1.8% 
of maximum light transmittance was observed in control experiments (n = 6; P < 0.05).   
 
   3.2.2 High-dose blebbistatin inhibits thrombin-evoked rises in [Ca2+]cyt elicited in 
the absence of extracellular Ca2+ in human platelets. 
Fura-2-loaded human platelets were preincubated with either 10, 30 or 100 µM 
blebbistatin, or an equivalent volume of its vehicle DMSO for 10 minutes at 37°C under 
continuous magnetic stirring. Blebbistatin was found to be autofluorescent when excited 
with 340 and 380 nm light, consistent with previous observations (Várkuti et al., 2016).  
To correct for this, calibration and autofluorescence measurements were performed in 
the presence of each concentration of blebbistatin. However the autofluorescent 
artefacts arising from platelets treated with 100 µM blebbistatin were too large to 
generate reliable data regarding their effect on thrombin-evoked Ca2+ signals, therefore 
these data are not presented here. Thrombin-evoked Ca2+ signals elicited in the 
absence of extracellular Ca2+ were not significantly inhibited by pretreatment with 10 μM 
blebbistatin (89.3 ± 5.3% of control; n = 6, P = 0.11; Fig. 3.6B), however a significant  
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Fig. 3.5 Blebbistatin prevents thrombin-evoked human platelet shape change. Washed human 
platelets were resuspended in supplemented HBS, and incubated with either 30 µM blebbistatin or an 
equal volume of DMSO for 10 minutes at 37°C. 1 mM EGTA was then added immediately prior to the 
start of experiment. Two minutes later, shape change was initiated by addition of 0.5 U/mL thrombin.  
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Fig. 3.6: Blebbistatin inhibits thrombin-evoked rises in [Ca
2+
]cyt elicited in the absence of 
extracellular Ca
2+
 in human platelets. Fura-2-loaded human platelets were resuspended into 
supplemented HBS and were incubated with either 10 µM blebbistatin (B), 30 µM blebbistatin (C), or an 
equal volume of DMSO ( ) for 10 minutes at 37  C. Extracellular Ca
2+
 was then chelated by addition of 1 
mM EGTA and cells were then stimulated 1 minute later by addition of 0.5 U/mL thrombin. 
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inhibitory effect was observed in the presence of 30 μM blebbistatin (61.7 ± 10.1  of 
control; n = 6, P < 0.05; respectively; Fig. 3.6C). These data are consistent with the 
possibility that nicergoline inhibits platelet function through inhibition of myosin. 
 
   3.2.3 Nicergoline inhibits thrombin-evoked Ca2+ signalling in both the presence 
and absence of low-dose blebbistatin 
To provide an initial assessment of whether nicergoline could elicit its effects on 
platelets through inhibiting myosin activity, experiments were performed to examine 
whether the inhibitory effect of blebbistatin was able to modulate the inhibitory effect of 
nicergoline when platelets were stimulated with thrombin in the absence of extracellular 
Ca2+. If the effects of blebbistatin in combination with nicergoline was greater than the 
effect of either inhibitor alone on platelet Ca2+ signalling, it would suggest that these 
inhibitors are working through distinct effects on this signalling pathway.  Therefore this 
would suggest that nicergoline is unlikely to be exerting its effect on platelet structure 
and function via an inhibitory effect on myosin. Initially Fura-2-loaded human platelets 
were pretreated with either 30 µM blebbistatin, or an equivalent volume of its vehicle 
(DMSO) for 10 minutes at 37°C under continuous magnetic stirring, and then further 
treated with either 100 µM nicergoline or an equivalent volume of DMSO for a further 10 
minutes under the same conditions.  However due to the relative insolubility of both 
nicergoline and blebbistatin, it was not possible to get reliable data from these 
experiments. Therefore these experiments were instead performed using 10 µM 
blebbistatin.  Previous studies have shown that 10 µM blebbistatin is sufficient to 
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significantly block myosin-dependent platelet functions such as internal contraction 
(Johnson et al., 2007). Pretreatment with 10 µM blebbistatin had no significant effect on 
thrombin-evoked rises in [Ca2+]cyt  compared to double DMSO-treated cells (107.9 ± 
3.6% of double DMSO-treated cells, n = 12, P = 0.06; Fig 3.7C). In contrast, 
nicergoline-pretreatment significantly reduced thrombin-evoked rises in [Ca2+]cyt  to 77.2 
± 3.0 % of double DMSO-treated cells (n =  12, P < 0.05, Fig. 3.7B), which was 
consistent with our previous findings (Walford et al., 2016).   
When platelets were pre-treated with both blebbistatin and nicergoline, there was still an 
inhibitory effect compared to cells treated with blebbistatin alone (n =12; P < 0.05). 
However when compared to control cells treated with nicergoline alone, the addition of 
nicergoline to blebbistatin-treated cells could not be observed to have any additional 
significant inhibitory effect (91.1 ± 4.3 % of double DMSO-cells; P = 0.07, Fig. 3.7D). 
These results therefore suggested the possibility that myosin could be the target of 
nicergoline. However this is difficult to be unambiguously stated from these experiments 
as it was not possible to utilize concentrations of blebbistatin able to completely inhibit 
myosin activity due to issues of solubility and autofluorescence of this compound. 
    
   3.2.4 Blebbistatin is incompatible with Fluo-based Ca2+ indicators 
Previously we have demonstrated that nicergoline inhibits thrombin-evoked Ca2+ 
removal into the extracellular fluid and release from intracellular stores (Walford et al., 
2016). These experiments utilize Fluo-4 salts to measure Ca2+ removal into extracellular 
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Fig. 3.7: Nicergoline is able to inhibit thrombin-evoked Ca
2+
 signalling in both the presence and 
absence of blebbistatin. Fura-2-loaded human platelet were resuspended in supplemented HBS and 
were incubated with either 10 µM blebbistatin (C,D) or an equal volume of DMSO (A,B) for 10 minutes at 
37°C. Cells were then incubated for a further 10 minutes with either 100  M nicergoline ( ,D) or an equal 
volume of DMSO ( ,C) at 37  C. 1 mM EGT  was then added 30 s after running the experiment. Cells 
were stimulated 1 minute later with 0.5 U/mL thrombin. 
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fluid, and Fluo-5N-loaded platelets to measure Ca2+ release from intracellular stores. As 
these two fluorescent indicators have distinct fluorescent properties to Fura-2, it was 
hoped that the autofluorescent properties of blebbistatin would have less interference at 
these wavelengths. Therefore experiments were performed to examine whether 
combined treatment with nicergoline and blebbistatin had cumulative effects to either 
treatment alone. However blebbistatin’s autofluorescent properties were also found to 
overwhelm the fluorescence of both fluo fluorescent indicators therefore making these 
experiments infeasible.  
 
   3.2.5 Blebbistatin has no inhibitory effect on thrombin-evoked rises in [Ca2+]cyt 
elicited in the presence of extracellular Ca2+. 
As nicergoline is also able to significantly inhibit thrombin-evoked Ca2+ signals elicited in 
the presence of extracellular Ca2+ (Walford et al., 2016), experiments were performed to 
examine if blebbistatin could replicate these effects. Pretreatment of Fura-2-loaded 
human platelets with blebbistatin at concentrations of either 10 μM or 30 μM had no 
significant effect on thrombin-evoked Ca2+ signals (90.2 ± 8.6% or 158.1 ± 59.1% of 
control, respectively (both n = 6, P > 0.05; Fig. 3.8). These data therefore indicate a 
significant difference between the pharmacological profile of blebbistatin and 
nicergoline, and suggests that myosin is not the target of nicergoline. 
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Fig. 3.8: Blebbistatin has no 
significant effect on thrombin-
evoked rises in [Ca2+]cyt elicited in 
the presence of extracellular Ca2+. 
Fura-2-loaded human platelets were 
resuspended in supplemented HBS 
and incubated with either 10 µM 
blebbistatin (B), 30 µM blebbistatin 
(C), or an equal volume of DMSO 
(A) for 10 minutes at 37  C. 
Extracellular CaCl2 was increased to 
1 mM at the start of the experiment. 
1 minute later, 0.5 U/mL thrombin 
was added to stimulate the cells. 
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   3.2.6 Blebbistatin has no effect on thrombin-evoked platelet aggregation.  
To confirm these findings, we examined the effect of blebbistatin on thrombin-evoked 
platelet aggregation elicited in the presence of extracellular Ca2+. As shown in Fig 3.9, 
pretreatment of washed human platelets with 30 μM blebbistation had no significant 
effect on either the maximum extent (84.6 ± 6.0% for DMSO-treated cells and 70.2 ± 
2.4% for blebbistain-treated cells; both n = 6; P > 0.05) or rate of platelet aggregation 
(99 ± 8 s for DMSO-treated cells and 103 ± 7 s for blebbistain-treated cells to reach 
maximum aggregation; both n = 6; P > 0.05). These results are distinct from nicergoline 
which significantly slows down the rate of platelet aggregation (see Section 3.1).  
Therefore these data suggest that myosin inhibition is not the primary mode of action of 
nicergoline. 
                                                 
 
Fig. 3.9: Blebbistatin has no effect on thrombin-evoked human platelet aggregation. Washed 
platelets were resuspended in supplemented HBS and incubated with either 30 µM blebbistatin or an 
equivalent volume of DMSO at 37°C for 10 minutes. CaCl2 was added to the cells prior the start of 
monitoring. Platelets were then stimulated with 0.5 U/mL thrombin. 
88 
 
  3.3 Investigating the effect of the dynein inhibitor, ciliobrevin A, on thrombin-
evoked human platelet function 
Dynein is a molecular motor protein that plays a key role in regulating many cellular 
functions including organelle transport and movement of microtubules (Varma et al., 
2008;   Akhmanova & Hammer, 2010). Recent work has demonstrated that dyneins play 
a key role in maintaining the structure of the cortical microtubule ring by providing an 
antagonistic force to that of the kinesin motors (Diagouraga et al., 2014; also see 
Section 3.4). Therefore alterations in the activity of dynein might be able to alter the 
cortical microtubule structure by creating a net force for kinesin-mediated 
rearrangements.  This could lead to the reorganization of the DTS bound to this 
structure, and thus alter platelet Ca2+ signalling (Walford et al., 2016). Ciliobrevin A has 
been previously demonstrated to be a specific reversible inhibitor of cytoplasmic dynein 
1 and 2 activity which can prevent dynein-induced microtubule sliding (Firestone et al., 
2012). Experiments were therefore performed to test whether ciliobrevin A treatment 
could mimic or modulate the action of nicergoline on platelet function. 
 
   3.3.1 Ciliobrevin A potentiates thrombin-evoked rises in [Ca2+]cyt and thrombin-
evoked reduction in [Ca2+]st elicited in the absence of extracellular Ca
2+ 
Previous studies have demonstrated that ciliobrevin A inhibits dynein activity in a dose-
dependent manner, with maximum inhibition observed at 100 µM without any significant 
alteration in kinesin activity (Firestone et al., 2012). Fura-2-loaded human platelets were 
preincubated with either 10, 50 or 100 µM ciliobrevin A, or an equivalent volume of its 
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vehicle DMSO for 30 minutes at 37°C under continuous magnetic stirring.  The initial 
experiments showed that ciliobrevin A significantly quenched the Fura-2 fluorescence at 
the higher concentrations (50 µM and 100 µM).  Although there was still a small residual 
quench of Fura-2 fluorescence at 10 µM ciliobrevin A, it was possible to overcome this 
effect by performing calibrations both in the presence and absence of this compound. 
When cells were pre-treated with 10 µM ciliobrevin A, thrombin-evoked Ca2+ signals 
elicited in the absence of extracellular Ca2+ were significantly potentiated to 120.6 ± 
3.8% of those in cells treated with an equal volume of DMSO (n = 5, P < 0.05; 
respectively; Fig. 3.10A,B). These data suggested the possibility that dynein might 
negatively regulate Ca2+ signalling in human platelets and therefore if nicergoline was to 
artificially activate dynein this might be a potential method of action by which nicergoline 
has its effect on platelet Ca2+ signalling.  
As it was not possible to make Fura-2-based [Ca2+]cyt measurements at concentrations 
of ciliobrevin A that are able to induce maximal inhibition of dynein (Firestone et al., 
2014), we instead attempted to make further measurements of thrombin-evoked Ca2+ 
signalling with the Fluo family of Ca2+ indicators as these have a distinct excitation and 
emission spectra from Fura-2. By doing this we hoped to overcome the quenching 
effects of ciliobrevin A at higher doses. Experiments using Fluo-5N-loaded platelets 
were performed to examine whether pretreatment with 100 µM ciliobrevin A affected 
thrombin-evoked Ca2+ release from intracellular Ca2+ stores, when cells were stimulated 
in the absence of extracellular Ca2+. Our experiments found that 100 µM Ciliobrevin A 
introduced an autofluorescence to the experiment, however it was possible to correct for 
this effect by measuring this fluorescent rise by adding the same concentration to a 
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sample of the HBS in which the platelet sample was resuspended.  By subtracting this 
autofluorescence we found that it was possible to nearly equalize the basal 
fluorescences (2.60 ± 1.88 arbitrary units for control cells and 2.65 ± 1.01 for ciliobrevin 
A-treated cells; n = 10; P > 0.05). However, there was a tendency for ciliobrevin A-
treated cells to have a higher basal fluorescence than untreated cells, therefore to 
ensure this did not affect the results all fluorescence values were analysed both in their 
initial format as well as when normalized to the basal fluorescence recorded prior to 
thrombin stimulation (F/F0). Pretreatment with 100 µM Ciliobrevin A for 30 minutes at 
37ºC was found to significantly potentiate thrombin-evoked Ca2+ release from 
intracellular Ca2+ stores when platelets were stimulated in the absence of extracellular 
Ca2+. This effect was observed when both the raw data traces (299.8 ± 35.4% of 
control; n = 10; P < 0.05; Fig 3.10) and the normalized traces (266.4 ± 39.7% of control; 
P < 0.05; Fig 3.10C,D) were analysed. These data suggest that the potentiation in 
thrombin-evoked cytosolic Ca2+ signals occurs due to an increased release of Ca2+ from 
the intracellular stores.  
 
   3.3.2 Pre-treatment with ciliobrevin A is unable to reverse the inhibitory effect of 
nicergoline on thrombin-evoked rises in [Ca2+]ext 
To further confirm these experiments and to assess whether dynein activation might be 
the mechanism by which nicergoline can inhibit agonist-evoked Ca2+ signalling in 
human platelets, we examined the effect of treating platelets sequentially with either 100 
µM ciliobrevin-A or an equal volume of its vehicle, DMSO, for 30 minutes at 37°C under  
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Fig. 3.10 Ciliobrevin A potentiates thrombin-evoked rises in [Ca
2+
]cyt and thrombin-evoked 
reductions in [Ca
2+
]st elicited in the absence of extracellular Ca
2+
. Fura-2- (A,B) or Fluo-5N- (C,D) 
loaded human platelets; were resuspended in supplemented HBS and incubated with either 100 μM 
ciliobrevin A (B,C,D) or an equal volume of DMSO (A,C,D) for 30 minutes at 37  C. 1 mM EGT  was 
added at the start of the experiment to chelate extracellular Ca
2+
. Cells were then stimulated 1 minute 
later by addition of 0.5 U/mL thrombin. (C) Fluo-5N fluorescence traces corrected for ciliobrevin 
autofluorescence. (D) shows the same traces as shown in (C) when the fluorescence values (F) are 
normalized to the basal fluorescence (F0) prior to thrombin stimulation. 
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constant magnetic stirring, followed by a further 10 minute incubation under the same 
conditions with either 100 µM nicergoline or an equal volume of its vehicle, DMSO. 
Extracellular Ca2+ was then chelated with 1 mM EGTA and platelets stimulated by the 
addition of 0.5 U/mL thrombin. 
To counter the autofluorescent effect of the ciliobrevin A, all data were calibrated for 
total extracellular Ca2+ concentration ([Ca2+]ext) using standard curves generated by 
adding known concentrations of Ca2+ to Fluo-4-containing HBS to which either 
nicergoline, ciliobrevin-A, both compounds or an equivalent volume of DMSO had been 
added. Prior to stimulation there was no significant difference in the mean [Ca2+]ext 
measured in double DMSO-treated control cells (221.1 ± 4.7 µM), nicergoline-treated 
cells (212.8 ± 2.7 µM), ciliobrevin-treated cells (223.1 ± 11.6 µM), and cells treated with 
both inhibitors (224.3 ± 6.4 µM; all n = 6; P > 0.05 for all comparisons). The free [Ca2+]ext 
is significantly smaller due to the presence of large concentrations of the Ca2+ chelator 
EGTA (e.g. the free [Ca2+]ext  for control cells can be calculated using the maxchelator 
software to be 17.7 nM which is significantly below the resting [Ca2+]cyt; Bers et al., 
2010). These data therefore demonstrate that our calibration could overcome the 
presence of the autofluorescent ciliobrevin-A compound. In agreement with our previous 
studies, nicergoline pretreatment significantly inhibited the thrombin-rise in [Ca2+]ext to 
58.3 ± 2.3% of DMSO-treated control cells (n = 6; P < 0.05; Fig 3.11B; Walford et al., 
2016).  In contrast, pretreatment with ciliobrevin-A significantly potentiated the thrombin-
evoked rise in [Ca2+]ext  (154.0 ± 14.2% of DMSO-treated control cells; n = 6; P < 0.05; 
Fig 3.11C). However when cells were sequentially treated with both compounds, the 
inhibitory effect of nicergoline was further exacerbated, with the thrombin-evoked rise in 
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[Ca2+]ext inhibited to 41.3 ± 4.5% of DMSO-treated control cells (n = 6; P < 0.05 
compared to all other conditions; Fig 3.11D).  These data therefore suggest that dynein 
activation is unlikely to be the mechanism of action by which nicergoline inhibits agonist-
evoked Ca2+ signalling in human platelets. 
 
   3.3.3 Ciliobrevin A inhibits thrombin-evoked rises in [Ca2+]cyt elicited in the 
presence of extracellular Ca2+  
To further assess the effect of ciliobrevin A on human platelet function, we also 
performed experiments to asesss the effect of ciliobrevin A on thrombin-evoked rises in 
[Ca2+]cyt elicited in the presence of physiological extracellular Ca
2+ conditions.  As 
shown in Fig 3.12, pretreatment of Fura-2-loaded cells with 10 µM ciliobrevin A had a 
tendency to have a small inhibitory effect on thrombin-evoked rises in [Ca2+]cyt elicited in 
the presence of extracellular Ca2+. However this effect did not reach statistical 
significance (70.9 ± 12.7% of DMSO-treated control cells; n = 9; P = 0.07). These 
results are also inconsistent with nicergoline having its effect through altering dynein 
activity in human platelets. These results also suggest that as well as negatively 
regulating Ca2+ release from intracellular stores, dynein may have an additional effect 
on facilitating activation of a Ca2+ permeable channel on the platelet plasma membrane. 
Further studies will be required to further examine this possibility. 
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Fig. 3.11: Pre-treatment with ciliobrevin A is unable to reverse the inhibitory effect of nicergoline 
on thrombin-evoked rises in [Ca
2+
]ext.  Washed human platelets were resuspended in supplemented 
HBS and incubated with either 100  M ciliobrevin    (C,D) or an equivalent volume of its vehicle, DMSO 
( , )  for 30 minutes at 37  C under conditions of continuous magnetic stirring. Following this cells were 
preincubated under the same conditions for a further 10 minutes with  either 100 µM nicergoline (B,D) or 
an equivalent volume of its vehicle, DMSO (A,C). 2.5 µM Fluo-4 salt was added to platelets just prior the 
start of monitoring the cells. 1 mM EGTA was added at the start of the experiment, and cells were 
stimulated 1 minute later with 0.5 U/mL thrombin. 
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Fig. 3.12: Ciliobrevin-A inhibits thrombin-evoked rises in [Ca
2+
]cyt elicited in the presence of 
extracellular Ca
2+
. Fura-2 loaded human platelets were resuspended in supplemented H S and 
incubated for 30 minutes with either 10 μM ciliobrevin   ( ) or an equal volume of DMSO ( ) at 37  C. 
Extracellular Ca
2+
 concentration was adjusted to 1 mM at the start of the experiment, and then cells were 
stimulated one minute later with 0.5 U/mL thrombin.  
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   3.3.4 Ciliobrevin A has no significant effect on thrombin-evoked platelet 
aggregation  
In line with the experiments done in the presence of extracellular Ca2+, the inhibitory 
effect exerted by ciliobrevin A on cytosolic Ca2+ did not correlate with any effect on 
platelet aggregation as pretreatment with 100 µM ciliobrevin A had no effect on the rate 
or extent of platelet aggregation, with both  maximum aggregation and time to reach 
maximum aggregation being similar between ciliobrevin-treated (77.8 ± 2.9% and 99.3 ± 
2.1 s respectively) and control cells (78.6 ± 3.4% and 102.7 ± 4.7 s respectively; n = 6; 
both P > 0.05; Fig. 3.13) suggesting this inhibitory effect has limited impact on platelet 
functionality. 
                                            
 
Fig. 3.13: Ciliobrevin A has no significant effect on thrombin-evoked human platelet aggregation. 
Washed human platelets resuspended in supplemented HBS were incubated with either 100 µM 
ciliobrevin A or an equal volume of its vehicle, DMSO for 30 minutes at 37°C. CaCl2 was added to the 
cells prior the start of the experiment. Platelets were then stimulated with 0.5 U/mL thrombin to initiate 
aggregation. 
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  3.4 Investigating the effect of an inhibitor of the motor protein kinesin on 
thrombin-evoked Ca2+ signalling in human platelets   
Previous studies have defined that kinesins function as molecular motor proteins that 
play a role in determining the distribution of organelles and secretory granules inside the 
cell (Marx et al., 2009). Previous work on platelets has demonstrated a role for kinesins 
in maintaining the normal structure of the resting platelet through maintaining the normal 
structure of the cortical microtubule bundle. Treatment of resting platelets with the 
kinesin-inhibitor, aurintricarboxylic acid was shown to induce spontaneous coiling of the 
cortical microtubules (Diagouraga et al, 2014). As this coiling induces platelets to 
become spherical with a re-organised cortical microtubule bundle, we performed 
experiments to examine whether this kinesin inhibitor can mimic or modulate the 
inhibitory effects of nicergoline on platelet function.  
 
   3.4.1 ATA inhibits thrombin-evoked rises in [Ca2+]cyt  in human platelets 
stimulated in the presence of physiological levels of extracellular Ca2+  
Previous studies have demonstrated that ATA acts in a dose-dependent manner to 
inhibit platelet function with a maximum effect at 30 µM (Takiguchi et al., 1996). Fura-2-
loaded human platelets were preincubated with 30 µM ATA, or an equivalent volume of 
its vehicle DMSO for 10 minutes at 37°C under continuous magnetic stirring. When 
platelets were stimulated with thrombin in the presence of physiological extracellular 
Ca2+ concentrations, thrombin-evoked rises in [Ca2+]cyt were significantly inhibited to 
14.2 ± 3.8% of control  (n = 6, P < 0.05, Fig. 3.14).  
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Fig 3.14: ATA inhibits the thrombin-evoked platelet rises in [Ca
2+
]cyt elicited in the presence of 
extracellular Ca
2+
. Fura-2-loaded human platelets were resuspended in supplemented HBS and 
incubated with either 30 µM ATA (B) or an equal volume of its vehicle, DMSO (A) for 10 minutes at 37ºC. 
Extracellular Ca
2+
 was raised to 1 mM and cells were then stimulated 1 minute later with 0.5 U/mL 
thrombin. 
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   3.4.2 ATA inhibits thrombin-evoked platelet aggregation  
To confirm these findings, additional experiments were performed to examine whether 
pretreatment with ATA could inhibit thrombin-evoked platelet aggregation. Fig. 3.15 
shows the effect of pretreatment of washed human platelets with either 30 µM ATA (or 
an equivalent volume of its vehicle, DMSO) for 10 minutes at 37°C under continuous 
magnetic stirring. ATA pretreatment significantly increased both the time to reach 
maximum aggregation (171.4 ± 3.0 s and 86.8 ± 8.7 s for ATA- and DMSO-treated cells 
respectively; n = 5; P < 0.05), as well as significantly inhibiting the maximum extent of 
platelet aggregation observed in thrombin-stimulated cells (56.0 ± 1.9% and 78.7 ± 
2.3% of maximum for ATA- and DMSO-treated cells respectively; n = 5; P < 0.05). 
These data suggest the inhibitory effect of ATA on rises in [Ca2+]cyt result in similar 
effects on platelet aggregation elicited under similar conditions. 
 
   3.4.3 ATA inhibits thrombin-evoked rises in [Ca2+]cyt  in human platelets 
stimulated in the absence of extracellular Ca2+, and has no cumulative effect 
when combined with nicergoline 
Further experiments were performed to examine whether this inhibitory effect of ATA 
could also be observed on platelet stimulated in the absence of extracellular Ca2+.  In 
addition, experiments were simultaneously performed to examine whether the inhibitory 
effect of ATA was cumulative with the inhibitory effect of nicergoline under these 
conditions.  If there is cumulative effect of these two inhibitors used together is greater 
than the effect of either inhibitor used alone, it would indicate they are working through 
distinct pathways, such that we could rule out the possibility that kinesins are the targets 
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of nicergoline. However if the effect of either inhibitor alone was similar in magnitude to 
that observed when both inhibitors are used together then this would indicate that these 
inhibitors could be working through inhibiting the same part of the Ca2+ signalling 
pathway. 
 
                 
 
Fig. 3.15: ATA inhibits thrombin-evoked platelet aggregation. Washed platelets were resuspended in 
supplemented H S and incubated with either 30  M  T  or an equivalent volume of DMSO at 37  C for 
10 minutes under continuous magnetic stirring. CaCl2 was added to raise it to a final concentration of 1 
mM. Platelets were then stimulated with 0.5 U/mL thrombin.  
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Initially Fura-2-loaded human platelets were pretreated with either 30 µM ATA, or an 
equivalent volume of its vehicle (DMSO) for 10 minutes at 37°C under continuous 
magnetic stirring, and then further treated with either 100 µM nicergoline or an 
equivalent volume of DMSO for a further 10 minutes under  the same conditions.  In line 
with our previous findings, pretreatment with nicergoline alone significantly inhibited 
thrombin-evoked rises in [Ca2+]cyt  compared to double DMSO-treated cells (75.2 ± 2.4% 
of double DMSO-treated cells, n = 5, P < 0.05; Fig 3.16B; Walford et al., 2016).  
Interestingly, cells pretreated with ATA alone inhibited thrombin-evoked rises in [Ca2+]ext 
more than nicergoline (33.9 ± 10.8% of double DMSO-treated cells (n =  5, P < 0.05 
against both nicergoline- and DMSO-treated cells, Fig 3.16C). When platelets were pre-
treated with ATA followed by nicergoline, the inclusion of nicergoline elicited no 
additional inhibitory effect compared to cells treated with ATA alone (35.8 ± 4.9 % of 
double DMSO-treated control cells; n = 5; P > 0.05; Fig 3.16D). These data therefore 
suggest the possibility that nicergoline could have its inhibitory effects through partially 
inhibiting kinesin activity.   
 
   3.4.4 ATA inhibits thrombin-evoked rises in [Ca2+]ext  and thrombin-evoked 
decreases in [Ca2+]st in human platelets  
To confirm these findings, further experiments were performed to examine the effect of 
ATA and nicergoline alone and in combination; on the thrombin-evoked rise in [Ca2+]ext. 
Washed platelets were suspended in supplemented HBS and treated with either 30 µM 
ATA or an equivalent volume of DMSO for 10 minutes, and then followed by  
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Fig. 3.16: ATA inhibits thrombin-evoked rises in
 
[Ca
2+
]cyt  in human platelets stimulated in the 
absence of extracellular Ca
2+
, and has no cumulative effect when combined with nicergoline. Fura-
2-loaded human platelets were resuspended in supplemented HBS, and incubated with either 30 µM ATA 
(C,D) or an equal volume of its vehicle, DMSO (A,B) for 10 minutes at 37C under continuous magnetic 
stirring. This was followed by a further incubation of cells for 10 minutes with either 100 µM Nicergoline 
(B,D) or an equal volume of its vehicle, DMSO (A,C) under identical conditions. 1 mM EGTA was added 
at the start of the experiment to chelate all extracellular Ca
2+
. Cells were then stimulated 1 minute later by 
the addition of 0.5 U/mL thrombin. 
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a further 10 minutes incubation with either 100  M Nicergoline or an equivalent volume 
of DMSO at 37  C under continuous magnetic stirring. Fluo-4 K+ salt was then added 
immediately before the start of the experiment to allow thrombin-evoked rises in the 
Ca2+ concentration of the extracellular medium to be measured.  Consistent with our 
previous findings, cells treated with nicergoline alone showed a significant reduction in 
thrombin-evoked rises in [Ca2+]ext to 49.0 ± 7.0% of double DMSO-treated cells (n = 6, P 
< 0.05; Fig. 3.17B). A similar inhibition was also obtained in cells pretreated with ATA 
(55.0 ± % of double DMSO-treated cells; n = 6, P < 0.05; Fig. 3.17C). Pretreatment with 
both ATA and nicergoline also inhibited the reduction in [Ca2+]ext rises to 33.9 ± 7.9% of 
control, although this was not significantly different from either treatment alone (n = 6, P 
< 0.05 compared to control; P > 0.05 for both single drug treatments; Fig. 3.17D). 
In addition, the same experiment was also conducted with Fluo-5N-loaded human 
platelets to examine how ATA and nicergoline affect thrombin-evoked Ca2+ release from 
intracellular stores when cells were stimulated in the absence of extracellular Ca2+. As 
can be seen in Fig 3.18, pretreatment with either ATA or nicergoline alone significantly 
inhibited the thrombin-evoked reduction in intracellular store Ca2+ concentration to 31.5 
± 11.1% and 72.3 ± 3.6% of double DMSO treated control cells for ATA- and 
nicergoline-treated cells respectively (both n = 6; both P < 0.05 compared to control).  In 
addition, cells treated with both compounds were found to have a reduction in the 
thrombin-evoked fall in [Ca2+]st to 43.5 ± 6.8% of control (n =6; P < 0.05).  Treatment 
with both ATA and nicergoline was found not to be significantly different from treatment 
with ATA alone (P > 0.05), in line with these compounds could be working via a 
common mechanism.   
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Fig.3.17: ATA inhibits thrombin-evoked rises in
 
[Ca
2+
]ext  in human platelets stimulated in the 
absence of extracellular Ca
2+
, and has no cumulative effect when combined with nicergoline. 
Washed human platelets were resuspended in supplemented HBS and incubated with either 30 µM ATA 
(C,D) or an equivalent volume of DMSO (A,B) for 10 minutes, followed by additional incubation with either 
100 µM Nicergoline (B,D) or an equivalent volume of DMSO (A,C) for another 10 minutes at 37  C. 2.5  M 
Fluo-4 salt was added to the cells just prior the start of experiment. 1 mM EGTA was then added at the 
start of the experiment to chelate extracellular Ca
2+
, followed 1 minute later by the stimulation of cells with 
0.5 U/mL thrombin. 
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Fig. 3.18 ATA inhibits thrombin-evoked reductions in
 
[Ca
2+
]st  in human platelets stimulated in the 
absence of extracellular Ca
2+
, and has no cumulative effect when combined with nicergoline Fluo-
5N-loaded human platelets were resuspended in supplemented HBS and incubated at 37°C with either 
30 µM ATA (C,D) or an equivalent volume of DMSO (A,B) for 10 minutes. Stirred platelet samples were 
further incubated with either 100 µM Nicergoline (B,D) or an equivalent volume of DMSO (A,C) for a 
further 10 minutes. 1 mM EGTA was then added to cells prior to the start of experiment. Cells were then 
stimulated with 0.5 U/mL thrombin 1 minute later. 
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    3.4.5 ATA inhibits thrombin-evoked shape change 
To examine whether the inhibition of Ca2+ signalling by ATA elicited concomitant 
changes in platelet functionality, experiments were performed to examine if platelet 
shape change elicited in the absence of extracellular Ca2+ was affected by pre-
treatment with this drug. Washed human platelets suspended in supplemented H S 
were preincubated for 10 minutes with either 30  M  T  or an equivalent volume of its 
vehicle, DMSO at 37  C under continuous magnetic stirring. EGT  was then added to 
chelate the extracellular Ca2+ prior the monitoring of samples in an aggregometer at 
37°C. As can be seen in Fig. 3.19, pretreatment with ATA significantly inhibited the 
magnitude of platelet shape change observed. A mean light transmittance decrease of 
10.0 ± 2.0% of maximum light transmittance was observed in DMSO-treated cells, 
compared to a mean decrease of 1.8 ± 0.9% of maximum light transmittance in ATA-
treated cells (n = 7; P < 0.05).  These data suggest that ATA pretreatment interferes 
with the normal shape change response of human platelets, as previously suggested by 
Diagouraga et al., (2014). 
 
   3.4.6 Incubation with ATA significantly inhibited the thrombin-evoked increase 
F-actin content in human platelets.  
Previous studies have been reported the importance of the actin cytoskeleton in the 
platelet shape that is elicited upon agonist stimulation (White & Burris, 1984; Johnson et 
al., 2007). In addition previous studies have also demonstrated that the actin 
cytoskeleton plays a key role in modulating platelet Ca2+ signalling (Harper & Sage, 
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Fig 3.19 ATA inhibits thrombin-evoked shape change.  Washed human platelets were resuspended in 
supplemented H S and incubated at 37  C with either 30  M  T  or an equivalent volume of its vehicle, 
DMSO for 10 minutes. EGTA was then added at 1 mM just before the start of the experiment. Cells were 
then stimulated with 0.5 U/mL thrombin. 
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2006; Harper & Sage, 2007; Rosado & Sage, 2000). Therefore, additional experiments 
were performed to identify if ATA treatment is able to affect platelet Ca2+ signalling by 
either altering the distribution of the cortical actin cytoskeleton in resting platelets or the 
amount of F-actin in resting and thrombin-stimulated human platelets. Resting platelets 
or platelets stimulated with thrombin for 1 minute were fixed and labelled with iFluor555-
labelled phalloidin.  Cells were then washed and fluorescence from phalloidin-tagged F-
actin was monitored using a microplate reader.  Each individual measurement was the 
mean of 3 fluorescence readings obtained from different samples of the labelled 
platelets. Under these conditions, ATA had no significant effect on the F-actin content of 
resting platelets (129.0 ± 14.0 % of control; n = 6; P = 0.09). These results were 
supported by analysis of these platelets by fluorescence microscopy after loading onto 
poly-L-lysine coverslips.  Assessment showed that ATA-treated platelets appear more 
rounded – similar to nicergoline-treated platelets (Walford et al.., 2016).   The cortical 
actin ring appeared unaffected in ATA-treated cells. Measurements were made of the 
thickness of the cortical actin ring using Image J analysis of the recorded pictures, and 
there was found to be no significant difference in the thickness of the cortical ring in 
both ATA-  (819 ± 48.nm; n = 56 cells) and DMSO-treated platelets (802 ± 33.nm; n = 
58 cells; P > 0.05; Fig 3.20). These data therefore suggest that despite the ATA-
induced coiling of the cortical microtubule bundles in resting platelets (Diagouraga et al., 
2013), there is no associated change in the distribution of F-actin in resting platelets. 
However upon thrombin stimulation in the absence of extracellular Ca2+, F-actin content 
of ATA-treated platelets showed significantly less increase in the F-actin content 
compared to DMSO-treated cells (44.3 ± 18.8% of control; n = 6, P < 0.05). 
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Fig. 3.20: The cortical F-actin ring appears unaffected in ATA-treated platelets. Platelets were 
treated with either 30 µM ATA (left panel) or DMSO (right panel) at 37ºC for 10 minutes under constant 
magnetic stirring. Cells were then fixed, permeabilised and labelled with phalloidin iFluor 555 dye. 
Platelets were then washed and loaded onto poly-L-lysine coated slides and cells left for 5 minutes to 
settle. Excess platelet suspension was then pipetted out and the slides were washed with PBS. Cells 
were then monitored for F-actin fluorescence using an Olympus Fluoview FV1200 confocal microscope. 
The results were obtained from cells from two different donors. 
 
As blocking F-actin polymerization with cytochalasin D has been shown to potentiate 
thrombin-evoked cytosolic Ca2+ signals under the same stimulatation conditions (Harper 
& Sage, 2006), these data therefore suggest the possibility that the ATA-induced 
impairment of the thrombin-evoked rise in cytosolic Ca2+ may prevent normal 
reorganization of the F-actin cytoskeleton. 
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   3.4.7 ATA inhibits thrombin-evoked dense granule secretion in human platelets  
Our previous studies have demonstrated that nicergoline inhibited platelet functionality 
at least in part through an inhibitory effect on dense granule secretion (Walford et al., 
2016). Therefore experiments were performed to examine whether ATA was able to 
elicit a similar inhibitory effect on this parameter here. Washed human platelets were 
resuspended in supplemented HBS and incubated at 37°C with 30 µM ATA or an equal 
volume of its vehicle, DMSO for 10 minutes under continuous magnetic stirring. EGTA 
and luciferin-luciferase was then added to the cells prior to thrombin stimulation. All 
values were normalized to the maximum luminescence values obtained at the end of 
each run by addition of 10 µM ATP to each sample. Thrombin-evoked dense granule 
secretion was found to be significantly inhibited in ATA-pretreated cells compared to 
control cells. Thrombin stimulation of DMSO-treated cells was found to elicit an increase 
in fluorescence of 7.4 ± 2% of maximum ATP secretion, whereas ATA-treated cells only 
elicited an increase of 0.8 ± 0.3% of maximum ATP secretion (n = 6; P < 0.05; Fig. 
3.21). These data therefore are consistent with kinesin being a potential molecular 
target of nicergoline in platelets.  
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Fig. 3.21: ATA inhibits thrombin-evoked dense granule secretion in human platelets. Washed 
human platelets were resuspended in supplemented HBS, and incubated at 37°C with 30 µM ATA or an 
equal volume of DMSO for 10 minutes at 37°C. EGTA was then added to cells followed by the addition of 
Luciferin-luciferase prior the start of experiment. Cells were then monitored before and after stimulation 
with 0.5 U/mL thrombin. All results normalized to a maximum value measured after the addition of 10 µM 
ATP to the sample at the end of the experiment. * = P < 0.05  
 
 
   3.4.8 ATA inhibits the generation of pericellular Ca2+ signalling in human 
platelets. 
Previous studies have demonstrated that it is possible to observe pericellular Ca2+ 
signals in single, thrombin-stimulated human platelets (Sage et al., 2013; Walford et al., 
2016). These pericellular Ca2+ rises were found to occur within an extracellular space 
found within the interior of the cell, consistent with their creation in the OCS. In addition, 
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they were found to originate within a specific sub-region of the cell – which has been 
shown to be likely created by the membrane complex (Sage et al., 2013; Walford et al., 
2016). If kinesin inhibition alters the normal positioning of the DTS in human platelets, it 
would be expected that it would disrupt the membrane complex and thus reduce the 
number of pericellular Ca2+ rises observed in ATA-treated cells.  Therefore, experiments 
were performed to examine whether the creation of pericellular Ca2+ hotspots was 
reduced in ATA pretreated cells. Thrombin stimulation evoked pericellular Ca2+ hotspots 
in 77.1 ± 5.0% of DMSO-treated control cells, whilst these Ca2+ signals were only 
observed in 41.0 ± 13.6% of ATA-treated cells taken from the same 5 donors (P < 0.05; 
Fig 3.22). These data are consistent with our previous findings in which nicergoline 
significantly reduced the proportion of cells producing these signals (Walford et al., 
2016). Therefore, these data further support the hypothesis that kinesin may be the 
target of nicergoline’s action in human platelets. 
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Fig. 3.22: ATA significantly inhibited the generation of the pericellular Ca
2+
 hotspots in thrombin 
activated human platelets.. Washed platelets were resuspended in supplemented HBS. Samples of 
platelet suspension were then preincubated with either 30 µM ATA or an equivalent volume of DMSO for 
10 minutes at 37°C. Samples were then treated with 1 mM EGTA before they were loaded onto poly-L-
lysine coated chambered coverslides and left to settle for 5 minutes prior to imaging. Fluo-4 salt was then 
added and mixed gently immediately prior to imaging. Cells were imaged before and 5 minutes after the 
addition of 0.5 U/mL thrombin by confocal microscopy. 
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4. Assessment of CD34+-cultured human megakaryocytes as a model system in 
which to study the effect of nicergoline on human platelets 
 
  4.1 Characterization of human CD34+ cell culture undergoing megakaryocytic 
differentiation. 
Initial experiments were performed to establish whether it was possible to successfully 
elicit megakaryocytic differentiation of CD34+ cells in culture using a previously 
published methodology (Pinault et al., 2013).  To do this CD34+ cells were plated into 
24-well plates and cultured in SFEM-IITM culture media with a cytokine cocktail 
containing Interleukin-6 (IL-6), Interleukin-9 (IL-9), Thrombopoietin (TPO) and Stem Cell 
Factor (SCF). Cells were examined for up to 14 days by light and fluorescence 
microscopy.  Initial results found that the largest cells were observable from days 7-9, 
and that cells often disappeared after this time point often with the appearance of cell 
fragments observable in the culture. These may have represented the production of 
proplatelets, but further examination will be required to assess this.   
Initial light microscopy experiments were performed to examine changes in cell 
morphology and colony formation on days 2 and 7 of the culture. As shown in Fig. 4.1A, 
by day 2 cells could be seen to clump into colonies within the liquid cultures.  Closer 
examination showed the cells on day 2 to have a uniform circular shape, with only one 
nucleus, visible as a central dark area surrounded by a narrow, very light and 
transparent rim of cytoplasm  indicative of an undifferentiated CD34+ cell (Fig. 4.1B).  t 
day 7, cells started to appear to have signs of megakaryocytic development 
recognizable by their irregular, larger size (Fig 4.1C, blue arrow). 
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Fig. 4.1: Light microscopy showing different stages of CD34
+
 cell growth and differentiation 
during the 14 day tissue culture. (A) Colony of CD34
+
 cells at an early stage of growth (Day 2, X4 
magnification). (B) Cells are starting a megakaryocytic differentiation (Day 2, X 20). (C) Cells are in an 
advanced stage of megakaryocytic maturation recognizable by their irregular larger size (blue arrow; day 
7, X 20). (D) Cells at their late stages of megakaryocytic maturation showing cells with distorted large size 
and markedly indented and lobed nucleus (red arrows) with cytoplasmic protrusions which might possibly 
be pro-platelets (yellow arrow; day 11, X 20). 
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 t day 11 (Fig. 4.1D) cells at the end stage of maturation showing the distorted large 
size of mature megakaryocyte with a markedly indented and lobed nucleus (red 
arrows), as well as cytoplasmic protrusions which might possibly be pro-platelets were 
present (yellow arrow). There were also less overall cells and a number of cellular 
fragments suggesting that megakaryocyte differentiation towards a platelet-shedding 
phenotype was occurring. 
Cultured CD34+ cells were also examined fluorescently for megakaryocytic 
differentiation on the same days. Cells were loaded with Hoechst 33342 to allow us to 
observe the nucleus and Fluo-5N to allow us to identify intracellular Ca2+ stores. The 
loaded cell suspension was then placed in a Poly-L-lysine-coated chambered coverslide 
and suspended in a supplemented HBS in which Rhod-5N tripotassium salt was added 
just before the start of imaging. The high Ca2+ present in the supplemented HBS 
allowed the Rhod-5N low-affinity fluorescent Ca2+ indicator to be used to indicate the 
presence of the extracellular fluid within the lumen of the demarcation membrane 
system (DMS; an invagination of the megakaryocyte plasma membrane)  as has been 
previously shown by other groups (Mahaut-Smith et al., 2003). 
On day 2 of culture, cells had a uniform circular shape with single nucleus (blue) 
suggesting these cells had yet to undergo significant megakaryocytic maturation (Fig. 
4.2A). The nucleus was surrounded by cytosol in which there was a fine structure of 
intracellular Ca2+ stores (green), suggesting no specific polarization of the stores in 
these cells . There was no red Rhod-5N fluorescence observed inside of the surface 
membrane indicating that the DMS had yet to develop in these cells.   
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On day 7 of culture, cells had a larger and completely irregular shape. In addition, 
fluorescent staining indicated that the cell nucleus could be seen to be multi-lobular 
indicative of endomitosis found during megakaryocytic differentiation of the cells ( lue; 
Kaushansky et al., 2010). In addition, the Rhod-5N fluorescence demonstrates the 
presence of a DMS, therefore further supporting the megakaryocytic differentiation of 
the cells (Fig. 4.2B).  Intracellular Ca2+ stores could still be seen over most of the cell, 
however there were puncta of bright spots observed suggesting that these are more 
localized in these cells.  
 
  4.2 Quantitative assessment of the megakaryocytic maturation of CD34+ cells in 
the in vitro liquid culture system. 
In order to assess the extent of megakaryocyte differentiation we scored all imaged 
cells from day 2 and day 7 for presence of known markers of platelet maturation 
(Kaushansky et al., 2010). The cells were assessed for cell diameter, nuclear lobulation 
and presence of DMS (Fig. 4.3). Mature megakaryocytes show diameters of between 
20-40  m in diameter, presence of an extensive DMS and multi-lobular nuclei in-line 
with the presence of endomitosis (Kaushansky et al., 2010). Therefore these 
parameters were measured in each of the day 2 and day 7 cultures and compared. 
Cells showing no megakaryocytic marker were classified as megakaryocyte lineage 
cells, whereas those showing 1 or more megakaryocytic markers were classified as 
developing cells. The data therefore showed that day 2 and day 7 cultured cells showed 
no significant difference in any of these markers. All of these factors were significantly 
improved in the developing cells compared to the megakaryocyte lineage cells on day 2 
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Fig. 4.2: Confocal microscopy of CD34
+
 cells showing the differences between day 2 and day 7 
megakaryocytic cell differentiation. CD34
+
 cells collected on day 2 (A) and day 7 (B) of megakaryocyte 
culture were incubated with Hoechst 33342 and Fluo-5N dye for 2 hours at 37°C. Cells were then 
resuspended in supplemented HBS and loaded onto chambered coverglass and left for 30 minutes to 
settle.  Rhod-5N dye was added just before the start of imaging the cells using laser-scanning confocal 
microscopy.  
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and day 7 indicating that a small subpopulation of day 7 cells had not responded to the 
culture conditions at all (around 15%).  Interestingly there was no significant difference 
in nuclear lobulation or DMS presence in day 2 and day 7 developing cells, but there 
was a difference in cellular size. These data therefore indicate that prolonged culture is 
required to allow CD34+ to expand to the same size as the mature megakaryocytes. 
Despite this our cultures did not show a large proportion of large diameter 
megakaryocytes, indicating that further refinement of our cultures may be required in 
the future. Overall these data indicated that in our hands it is possible to develop 
megakaryocytic lineage cells from CD34+ cells, but that the final stages of maturation 
either do not occur or are transient and so are not observed here.  
Lastly we examined the images for possible presence of the MC. By overlaying the 
Fluo-5N and Rhod-5N data (after filtration of background fluorescence) it was possible 
to observe areas in which the two membrane systems coalesced suggesting the 
possible presence of a MC-like structure in these cells. These results therefore suggest 
the possibility that these cells may provide a potential model in which to study the 
platelet MC. 
 
  4.3 Quantitative measurement of megakaryocyte maturation by the assessment 
of expression of cell surface markers of this lineage 
To further analysis the maturity of our megakaryocytes we performed single cell analysis 
of the expression of known cell-surface markers of mature megakaryocytes – CD42b 
(part of the integrin αIIbβ3 complex, a platelet receptor for fibrinogen) and CD41a (the 
GPIb antigen for binding vWF; Pineault et al., 2013). Cells were fixed on day 2 and day 
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Fig. 4.3: Day 7 cells show an increase in megakaryocytic markers, and formation of a membrane 
complex-like structure. (A-D) The progress of maturation was judged by a special scale of parameters 
including cell diameter (A), nuclear lobulation (B) and DMS development (C). Cells are representative of 
cells taken from 4 different cultures covering 35 and 36 cells for day 2 and 7 respectively. (D) Each cell in 
the culture observed was scored for each of the 3 maturation markers identified in A-C, the proportion of 
cells showing 0, 1, 2 or 3 of these indices is shown. Overlaid fluorescence shows the presence of foci of 
co-localisation of DMS and intracellular Ca
2+
 stores (white arrows) which are indicative of structures 
potentially analogous to the MC (E). 
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7 of the culture and incubated with APC-labelled CD41a and FITC-labelled CD42b 
antibodies. Initial attempts were made to use flow cytometry to assess the maturation 
status of the culture, but due to the financial requirement to keep cell numbers low in 
each experiment, this was found to not be feasible. Therefore we examined the 
expression by fluorescent microscopy (Fig. 4.4). Only 23.4% of cells were found to 
stain positive for both markers on day 2 of the culture, whilst 83.8% of the cells were 
found to stain on day 7. Mean fluorescence for CD41a was found to be 1261 ± 180 
arbitrary units for day 7 cells (n = 38) and 31 ± 21 for day 2 cells (n = 14; P < 0.05). 
Similar results were found for CD42b-labelling with mean fluorescence of 1221 ± 177 for 
day 7 cells and 41 ± 28 for day 2 cells (P < 0.05). These data therefore confirmed that 
day 7 cells are megakaryocytic in lineage. 
 
  4.4 Nicergoline does not elicit a reorganisation of intracellular Ca2+ stores in 
CD34+-derived cultured human megakaryocytes 
Our previous work has indicated that nicergoline induces a microtubule-dependent 
redistribution of intracellular Ca2+ stores in human platelets (Walford et al., 2016). To 
examine whether similar structural effects are observed in human megakaryocytes, we 
examined whether treatment of day 7 CD34+-derived human megakaryocytes with 100 
 M nicergoline altered the distribution of the intracellular Ca2+ stores.  s can be seen in 
Fig. 4.5, treatment of cells with nicergoline elicited a loss of the bright puncta of  
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Fig. 4.4 Expression of cell surface markers of megakaryocyte lineage is greater on day 7 cells. 
CD34
+
 cells were harvested on day 2 (upper panels) and 7 (lower panels) of megakaryocyte culture and 
fixed in formaldehyde solution. Fixed cells were then labelled with fluorescently-labelled antibodies to the 
megakaryocyte cell surface markers, CD41a and CD42b.  The labelled cells were then analyzed by 
confocal microscopy. *P < 0.05, n = 14 and 38 cells for day 2 and day 7, respectively. Cells are 
representative of 3 different CD34
+
 cultures. 
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intracellular Ca2+ stores observed in the cell prior to treatment, with the store distribution 
appearing more homogenous. Numerical analysis of the distribution of Fluo-5N 
fluorescence across the cell indicated no significant difference in the mean fluorescence 
across the cells (598 ± 88 arbitrary units and 580 ± 82 before and after nicergoline 
treatment respectively; n = 11; P > 0.05).  nalysis of the variance of pixel fluorescence 
also indicated no significant difference before and after nicergoline treatment (standard 
deviation of pixel fluorescence was 525 ± 31 arbitrary units and 474 ± 38 before and 
after nicergoline treatment respectively; n = 11; P = 0.24). These results therefore 
indicate that nicergoline does not significantly alter the distribution of the intracellular 
Ca2+ stores across the megakaryocyte. This may be due to the endoplasmic reticulum 
and other Ca2+ stores behaving differentially to nicergoline treatment.  Further 
experiments using a more specific endoplasmic reticulum marker, the fluorescently-
labelled anti-KDEL antibody used during our previous study may help address this more 
effectively (Walford et al., 2016).  
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Fig. 4.5: Nicergoline does not induce a reorganisation of Fluo-5N-labelled intracellular Ca
2+
 stores. 
Day 7 cultured CD34
+
 cells were stained with Hoechst 33342 (nucleus; blue) and Fluo-5N (intracellular 
Ca
2+
 stores; green). Cells were the resuspended into a supplemented HBS containing Rhod-5N salts to 
label the demarcation membrane system (red).  Cells were then loaded onto a poly-L-lysine-coated 
chambered cover slide and examined under the Olympus Fluoview confocal microscope (upper panel). 
Cells were reexamined 5 minutes later after the addition of 100 µM nicergoline (lower panel).  
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  4.5 Nicergoline appears to inhibit thrombin-evoked pericellular Ca2+ 
accumulation in thrombin-stimulated CD34+-derived human megakaryocytes. 
Previous experiments on human platelets showed that nicergoline disrupts thrombin-
evoked Ca2+ signalling by inhibiting pericellular Ca2+ recycling (Le Menn et al., 1979; 
Parker et al., 1993; Sage et al., 2013). Experiments were therefore performed to 
examine if nicergoline pre-treatment could inhibit thrombin-evoked rises in cytosolic and 
pericellular Ca2+ concentration in the CD34+-derived human megakaryocytes. Day 9 
cultured megakaryocyte cells were co-loaded with Hoechst and Fluo-2 dyes, washed 
and preincubated with either 100 µM nicergoline or an equivalent volume of DMSO.  
The cells were then allowed to adhere to a poly-L-lysine-coated chambered coverslide 
in supplemented HBS containing 5 µM Rhod-5N salt. Fluorescence readings for Fluo-2 
were taken continuously before and after stimulation with 0.5 U/mL thrombin to assess 
changes in cytosolic Ca2+ concentration, whereas images of Rhod-5N were taken 
before thrombin stimulation and at the end of the 5 minute recording period to assess 
changes in the pericellular Ca2+ concentration. Unfortunately it was not possible to 
measure changes in cytosolic Ca2+ concentration as Fluo-2 fluorescence was found to 
photobleach rapidly through the recording period, making interpretation of the data 
difficult. The Rhod-5N fluorescence measurements showed that control cells 
demonstrated an increase in the pericellular Ca2+ concentration after thrombin 
stimulation (120.7 ± 6.1% of pre-stimulation fluorescence; n = 16), which was decreased 
by pretreatement with nicergoline (103.4 ± 5.9% of pre-stimulation fluorescence; n = 
11). However this effect was not statistically significant (P = 0.058). Further experiments 
will be required to confirm this preliminary finding.   If confirmed, this effect is consistent 
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with the possibility of megakaryocytes utilizing a pericellular Ca2+ recycling system in a 
similar manner to human platelets (Sage et al., 2013; Walford et al., 2015). 
 
  4.6 Nicergoline may inhibit thrombin-evoked rises in [Ca2+]cyt in CD34
+-derived 
human megakaryocytes  
Our previous studies have shown that nicergoline is able to inhibit thrombin-evoked 
rises in [Ca2+]cyt (Walford et al., 2016). Experiments were therefore performed to find out 
whether nicergoline can exhibit a similar inhibitory action on the Ca2+ signals in cultured 
megakaryocytes upon stimulation with thrombin. Therefore, cultured human 
megakaryocyte cell samples were harvested on day 7-9 of the culture and loaded with 
Fura-2, and thrombin-evoked changes in [Ca2+]cyt were then assessed using a 
fluorescence microplate reader.  Preliminary findings indicated that pretreatment with 
nicergoline elicited a consistent reduction in cytosolic Ca2+ signalling in cells stimulated 
in the presence of extracellular Ca2+. However these effects are not significant at this 
time (25.3 ± 13.1% of control; n = 5; P = 0.25; Fig 4.6). These results suggesting that 
the inhibitory effect of nicergoline on Ca2+ signalling in human platelets is also seen in 
human CD34+-derived human megakaryocytes, although further experiments will be 
required to complete these preliminary findings. 
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Fig 4.6: Nicergoline may inhibit thrombin-evoked rises in [Ca
2+
]cyt in CD34
+
-derived human 
megakaryocytes. Fura-2-loaded cultured human megakaryocyte cells were resuspended in 
supplemented HBS, and treated with either 100 µM nicergoline or an equal volume of its vehicle, DMSO.  
Extracellular Ca
2+
 was then raised to 1 mM immediately prior to the start of the experiments. Fura-2 
fluorescence was then monitored using a microplate reader before and after stimulation with 0.5 U/mL 
thrombin. 
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5. Discussion 
Previous work in our lab has demonstrated that nicergoline exerts its inhibitory effect on 
Ca2+ signalling in human platelets through triggering reorganisation of the cortical 
microtubule bundle (Walford et al., 2016). Based on the structural observations 
previously observed by Walford et al. (2016), the study authors suggested the possibility 
of an effect of this drug on either a change in the post-translational modifications of the 
cortical microtubule bundle or an alteration in the activity of microtubule-dependent 
motor proteins. In this project, experiments have been performed to attempt to examine 
each of these hypothesised mechanisms, with the aim of identifying the molecular 
mechanisms by which nicergoline exerts its inhibitory effect on human platelets.  
 
   5.1 Does nicergoline inhibit platelet Ca2+ signalling through an effect on the 
acetylation status of platelet microtubules?   
Our studies of the effect of inhibiting microtubule deacetylation with the deacetylase 
inhibitor, trichostatin A, have demonstrated that this compound has minimal effect on 
both platelet Ca2+ signalling and platelet function. In addition, this drug has no direct 
effect on mitigating the effect of nicergoline when platelets are incubated with both 
drugs. These findings therefore suggest that microtubule acetylation is unlikely to be the 
target of nicergoline.    
These findings are interesting as previous studies in human platelets have 
demonstrated that inhibition of the main microtubule deacetylase, HDAC6, is able to 
inhibit collagen-evoked aggregation (Aslan et al., 2013). This is distinct from our findings 
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here with thrombin where we find that inhibitors of this enzyme have no significant effect 
on platelet Ca2+ signalling or aggregation.  These results therefore suggest that 
thrombin- and collagen-evoked signalling pathways are differentially affected by this 
inhibitor.  Further studies should investigate whether microtubule acetylation affects 
collagen-evoked Ca2+ signalling through the PLCγ pathway in a distinct manner from 
the PLCβ-mediated thrombin-evoked signalling.  
Whilst our findings rule out microtubule acetylation as a potential target of nicergoline, it 
is worth noting that there are many other post-translational modifications of tubulin that 
have not been explored in this study. Currently acetylation is the best studied, with 
minimal study of other post-translational modifications such as detyrosination, 
(poly)glutamylation and (poly)glycylation. Therefore additional studies of the existence 
and functional significance of these pathways may provide future areas of study. 
 
  5.2 Does nicergoline inhibit platelet Ca2+ signalling through an effect on platelet 
myosin?   
Our attempts to assess the potential role of myosin as the target of nicergoline have 
been hampered by the autofluorescent properties of its specific inhibitor, blebbistatin.   
Due to interference with the readings obtained from all of the major fluorescent Ca2+ 
indicators we could use, this has prevented us from assessing the effect of blebbistatin 
and nicergoline in combination. However we have been able to assess the effect of 
blebbistatin alone on platelets. Previous studies showed that blebbistatin was able to 
abolish internal contraction at doses between 10-25 µM after 30 seconds of exposure to 
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this drug (Johnson et al., 2007). Therefore after 10 minutes of preincubation, the 10 and 
30 µM doses should provide significant inhibition of myosin activity in these cells. This is 
consistent with our shape change data in which 30 µM blebbistatin abolished thrombin-
evoked shape change (Fig. 3.5), consistent with the known role of myosin in this 
platelet response (Paul et al., 1999).  However whilst shape change was inhibited there 
was no effect of this treatment on thrombin-evoked aggregation or Ca2+ signalling 
elicited in the presence of extracellular Ca2+. This is a distinct pharmacological profile 
from the effect of nicergoline, and therefore provides strong evidence that nicergoline 
isn’t working through inhibition of myosin in human platelets.    
The inhibitory effect of blebbistatin on thrombin-evoked Ca2+ signalling in the absence of 
extracellular Ca2+ is similar to that seen with nicergoline (Walford et al., 2016). These 
results could indicate an effect on Ca2+ release, possibly by inhibiting pericellular Ca2+ 
recycling (Sage et al., 2013). However this result appear  inconsistent with those on 
Ca2+ entry as impaired Ca2+ release should also block Ca2+ entry, via inhibition of store-
operated Ca2+ entry (Berna-Erro et al., 2016). Therefore this indicates the possibility 
that these results may be the result of the effect of the blebbistatin quenching the Fura-2 
fluorescence in an inconsistent manner, such that calibrating in the presence of the drug 
is not able to compensate for this. Further studies will be needed to examine if this is a 
bone fide effect of the drug or an artefactual effect of the autofluorescent properties of 
the drug. Future work should be able to assess this using a highly soluble, non-
fluorescent blebbistatin derivative which has recently been reported (Várkuti et al., 
2016). These should provide us with a definitive conclusion regarding the role myosin 
plays in controlling platelet Ca2+ signalling. However the lack of effect of blebbistatin on 
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platelet aggregation indicates that nicergoline is unlikely to be working via an effect on 
myosin. 
 
  5.3 Does nicergoline inhibit platelet Ca2+ signalling through an effect on platelet 
dyneins?   
Our initial findings demonstrated that dyneins appear to play a role in negatively 
regulating Ca2+ release from intracellular stores as thrombin-evoked rises in [Ca2+]cyt 
elicited in the absence of extracellular Ca2+ are enhanced when dyneins are inhibited. 
This was consistent with the effect of this drug in potentiating thrombin-evoked depletion 
of intracellular stores as well as rises in extracellular Ca2+ concentration under similar 
conditions. These results therefore suggested the possibility that nicergoline could work 
by acting as an activator of dyneins. However further studies examining the effect of co-
incubation of ciliobrevin   with nicergoline suggested that this wasn’t the case, as this 
treatment lead to no reversal of the inhibitory effect of nicergoline. Thus these results 
suggest that whilst dyneins may have an inhibitory effect on Ca2+ signalling these are 
not the molecular targets of nicergoline in human platelets. 
Previous studies in primate cells has demonstrated that dyneins can play a key role in 
positioning of the endoplasmic reticulum through triggering rapid movement towards the 
centre of the cell (Wozniak et al., 2009). Given that platelet activation has been shown 
to trigger increased dynein activity, leading to the coiling of the platelet microtubule 
bands (Diagouraga et al., 2014), there is a possibility that dyneins have an inhibitory 
effect by rapid reorganization of the DTS which reduces its sensitivity to IP3 signals. 
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Indeed previous studies have described rapid, Ca2+-dependent change in the DTS 
ultrastructure, which would be consistent with a role for dyneins (Ebbeling et al., 1992).  
Future studies assessing this effect may therefore provide novel findings on how Ca2+ 
signalling is controlled in human platelets.  
The tendency towards an inhibitory effect of ciliobrevin A on thrombin-evoked Ca2+ 
signals when platelets were stimulated in the presence of extracellular Ca2+ suggests 
that Ca2+ entry pathways must be partially inhibited by this treatment to counter the 
effect of the increased Ca2+ release from intracellular Ca2+ stores. However this effect 
must be a mild one as no effect of this drug is observed on platelet aggregation in the 
same conditions.  Further studies will need to more fully characterise the effect of 
ciliobrevin A on Ca2+ signalling in the platelet to understand this effect further. 
 
  5.4 Does nicergoline inhibit platelet Ca2+ signalling through an effect on platelet 
kinesins?   
The data presented here examining the effect of the kinesin inhibitor, aurin tricarboxylic 
acid, showed a pharmacological profile consistent with the effects of nicergoline on 
platelet Ca2+ signalling – with a similar inhibition of thrombin-evoked rise in [Ca2+]cyt, 
depletion of intracellular Ca2+ stores,  inhibition of pericellular Ca2+ rises, platelet 
aggregation and dense granule secretion (Lanza et al., 1986; Walford et al., 2016). 
Furthermore the effect of ATA and nicergoline was not cumulative suggesting that they 
may be working through a related signalling pathway. Interestingly ATA was a more 
potent inhibitor of Ca2+ signalling in human platelets than nicergoline - therefore 
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suggestive that if nicergoline does work via this mechanism, it may only work through 
partially inhibiting kinesins in platelets. However further experiments will need to directly 
assess the impact of nicergoline on platelet kinesin activity before we can definitively 
conclude this. Previous studies by Diagouraga et al., (2013) have demonstrated the 
impact of ATA on microtubule structure. They demonstrated that this drug induces 
activation-independent coiling of the platelet microtubules, which appears to produce a 
similar partial disruption of the cortical bundle seen in a large proportion of the 
nicergoline-treated cells (Walford et al., 2016). These data therefore suggest that 
nicergoline may disrupt the normal structure of the microtubule bundle not through 
dismantling it, but through its ability to induce microtubule folding by a dynein-
dependent mechanism (Diagouraga et al., 2013). As the DTS is attached to these 
microtubules (Behnke, 1965) this will likely induce its redistribution across the cell 
through an indirect effect on the microtubules. The previous demonstration that 
nicergoline’s effect could be prevented by pre-treating with taxol to stabilise the cortical 
microtubules, would be consistent with this being the method by which nicergoline 
induces the reorganisation of the intracellular stores.  Further experiments will be 
required to examine if  T ’s effect on Ca2+ signalling can also be prevented by prior 
treatment with taxol.   
Kinesins also play a role in directly moving intracellular organelles around the cell 
through their motor activity directed towards the plus end of microtubules (Wells et al., 
1999; Marx et al., 2009). Interestingly, kinesins have previously been shown to play a 
significant role in regulating the granule motility in platelets (Cerecedo et al., 2010).  
Given that our previous study demonstrated a secondary microtubule-independent 
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effect of nicergoline on dense granule secretion (Walford et al., 2016) which was not 
related to the dismantling the membrane complex, it is possible that both the 
microtubule-dependent and -independent effects could both be mediated via inhibition 
of kinesins – with kinesin inhibition triggering coiling of the microtubule bundle to disrupt 
the membrane complex (Diagouraga et al., 2013; Walford et al., 2016), as well as 
separately interfering with the normal kinesin-mediated distribution of dense granules in 
the cell, such that dense granule secretion is inhibited. Consistent with this possibility 
we find that dense granule secretion is inhibited by ATA pretreatment. This possibility is 
an interesting one and therefore provides us with further circumstantial evidence that 
suggests that kinesin inhibition may be the target of nicergoline.   
Whilst our results suggest that nicergoline may partially inhibit kinesin activity, future 
work will also need to examine whether this is a direct effect of this drug on kinesin 
activity, or whether it is an indirect interaction with the systems that regulate kinesin 
activity (Gibbs et al., 2015). For instance, nicergoline has previously been shown to 
stimulate PKC activity, which could directly regulate kinesin activity (Gibbs et al., 2015) 
as well as trigger cleavage of the amyloid precursor protein, which acts as an adaptor 
protein to assist kinesin interaction with the organelles (Cedazo-Minguez et al., 1999; 
Gibbs et al., 2015). Understanding this mechanism of action of nicergoline better will 
help guide future drug development of anti-platelet agents to mimic the effect of 
nicergoline, by identifying the precise effect of this drug on platelets. 
 
  
135 
 
  
  5.5 Are CD34+-derived megakaryocytes a model system in which we can study 
the mechanism of action of nicergoline in human platelets?  
One of the major limitations of our current studies into how nicergoline may work is the 
difficulty of working with human platelets. Due to our inability to genetically modify these 
cells we are reliant on the presence of accessible pharmacological agents to target our 
pathways of interest – however as can be seen in this report, many drugs have issues 
surrounding solubility or autofluorescence which make them problematic to work with. 
The ability to genetically knockdown particular proteins in the nucleate megakaryocytic 
cell would provide us with another method in which to confirm our findings. In this 
project, attempts were made to establish a CD34+-derived cell culture system in which 
to generate human megakaryocytic cells in which we could investigate the effect of 
nicergoline.   
These pilot studies using previously published methodology (Pineault et al., 2013), 
demonstrated that it was possible to create human megakaryocytes, although it was 
difficult to capture a significant proportion of them at the sizes expected of a fully-
matured cells. Further work optimising the culturing conditions may facilitate this better.  
However cells could still be observed to possess membrane complex-like structures 
made up of the apposition of the demarcation membrane system and intracellular Ca2+ 
store (Fig 4.3). Recent work has also identified the close apposition between the DMS 
and the DTS-like, smooth endoplasmic reticulum (Eckly et al., 2014) – thus suggesting 
that we might be observing these structures in our cells.  These initial results therefore 
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suggested that these cells could be useful for modelling nicergoline-induced changes in 
the platelet ultrastructure. However our initial studies to assess this further 
demonstrated that nicergoline did not significant delocalise the intracellular Ca2+ stores 
in human platelets, with similar distributions of Fluo-5N fluorescence observed in cells 
before and after nicergoline treatment. This is different from our findings in human 
platelets in which the Fluo-5N could be found to be significantly more homogenously 
distributed across the cell after nicergoline treatment (Walford et al., 2016). One 
possibility is that the Fluo-5N is not selective solely for the smooth endoplasmic 
reticulum and so disruption of the membrane complex structure may still occur in these 
cells, but is not observed due to the positioning of other Ca2+-storing organelles not 
being disrupted by this treatment. Further studies utilising more specific probes for the 
endoplasmic reticulum may clarify this possibility. 
Initial studies examining the effect of nicergoline on the thrombin-evoked Ca2+ signals in 
these cells indicated the possibility that this drug also inhibited rises in cytosolic and 
extracellular Ca2+ concentration, although these results had not quite reached statistical 
significance. Further work will be required to complete these pilot studies and 
investigate if they are responsive to reversal by taxol pre-treatment to prevent 
microtubule remodelling as we saw in the original paper (Walford et al., 2016).  
At this time it is not possible to conclude on whether CD34+-derived megakaryocytes 
are a good model for studying the effect of nicergoline in human platelets, however our 
initial data suggest that they may at least provide a system in which we could study the 
formation of the membrane complex.    
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  5.6 Conclusion 
In this study we have demonstrated a key role for motor proteins in controlling thrombin-
evoked Ca2+ signalling and changes in human platelet function. These data have 
indicated that the most likely target for nicergoline’s ability to block platelet Ca2+ 
signalling is the ability to interfere with kinesin activity in the resting platelet.  This effect 
could explain the microtubule-dependent reorganization of the dense tubular system’s 
distribution in the platelets, as well as the potential for interfering with granule secretion 
in platelets. Interestingly the effect of ciliobrevin A in potentiating Ca2+ signalling in 
human platelets, suggests the possibility that Ca2+ release may be differentially 
controlled by the antagonistic action of these two molecular motors. Future work will be 
required to assess whether nicergoline can directly affect kinesin activity, or works via 
an indirect effect on a regulatory signalling pathway or an adaptor for kinesin transport. 
This study has expanded our understanding of the known anti-platelet effect of 
nicergoline.  By further refining our understanding of the direct molecular target of 
nicergoline we may be able to design novel anti-platelet agents which can specifically 
target the mechanisms controlling the normal positioning of the dense tubular system 
within the platelet, and as such downregulate agonist-evoked Ca2+ signalling. 
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